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Articles 
THE GLOBAL REACH OF HIV/AIDS: 
SCIENCE, POLITICS, ECONOMICS, AND 
RESEARCH* 
Lawrence O. Gostin** 
A constant theme in all our messages has been that, in 
this inter-dependent and globalized world, we have 
indeed again become the keepers of our brother and 
sister. That cannot be more graphically the case than 
in the common fight against HIV/AIDS. 
Nelson Mandela, Former President of South Africa 
(2001). 
HIV/AIDS affects people throughout the world-their 
health, their communities, and their countries' economic 
structures. It is truly a global epidemic, imposing a burden 
on all countries and regions, leaving none immune from its 
devastating impact. 1 Forty-two million people are infected 
with HIV,2 with one-third of the cases among youth ages 
fifteen to twenty-four. 3 Almost ninety percent of people 
* This Article is taken from a chapter on the global HIV/AIDS pandemic in a 
forthcoming book, LAWRENCE O. GOSTIN, AIDS IN AMERICA: THE LIMITS OF 
TOLERANCE (University of North Carolina Press, forthcoming 2003). The author 
acknowledges the extraordinary assistance of Georgetown University Law Center 
law student Elizabeth Geddes. 
** Lawrence O. Gostin is a Professor of Law at Georgetown University; Professor 
of Public Health, the Johns Hopkins University; Director, Center for Law and the 
Public's Health (CDC's Collaborating Center Promoting Health Through Law); and 
Research Scholar, Oxford University, Centre for Socio-Legal Studies. 
1 See generally Bernhard Schwartlander et al., AIDS in a New Millennium, 289 
SCI. 64 passim (2000) (providing statistics demonstrating the pandemic nature of 
AIDS). 
2 UNAIDS & WORLD HEALTH ORG., AIDS EPIDEMIC UPDATE 3 (2002), available 
at http://www. unaids.org/worldaidsday/2002lpress/update/epiupdate2002_en.doc 
(last visited Apr. 7, 2003) [hereinafter AIDS EPIDEMIC UPDATE 2002]. 
3 UNITED NATIONS CmLDREN'S FUND (UNICEF), UNAIDS, & WHO, YOUNG 
PEOPLE AND HIV/AIDS: OPPORTUNITY IN CRISIS (2002) [hereinafter UNICEF, 
UNAIDS & WHO]; TODD SUMMERS ET AL., THE TIP OF THE ICEBERG: THE GLOBAL 
IMPACT OF HIV/AIDS ON YOUTH 3 (2002), available at http://www.kiI.org/ 
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living with HIV/AIDS live in developing countries,4 which 
can least afford the sickness, death, and loss of productivity 
associated with the epidemic (See Map 1). 
contentl2002l6043/6043v3.pdf (last visited Apr. 14,2003). 
4 UNAIDS & THE WORLD BANK, HIV AND HUMAN DEVELOPMENT: THE 
DEVASTATING IMPACT OF AIDS 3 (1999). 
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Map 1: Adults and children estimated to be living with 
HIV/AIDS as of the end of 2002* 
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* Source: AIDS Epidemic Update 2002, supra note 2, at 35. 
3 
If the current trend continues, there will be 100 million 
people infected with HIV by 2006, thereby becoming the 
worst pandemic since the Black Death swept through 
Europe in the fourteenth century and killed one in four 
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people.5 In 2002 alone, three million people died from 
AIDS.6 More than twenty million people have already died 
from AIDS since it was first identified in the early 1980s7 
(See Map 2). 
5 David F. Gordon, The Next Wave of HN/AIDS: Nigeria, Ethiopia, Russia, 
India, and China, National Intelligence Council 10 (Sept. 2002) (projecting 75 
million cases of HIV in five of the world's most populous countries by 2010), 
available at 
http://www.cia.gov/nic/pubs/other_products/ICA%20HIV AIDS%20unclassified%2009 
2302POSTGERBER.pdf (last visited Apr. 10, 2003); John Donnelly, World's AIDS 
Crisis Worsening: Report Says Disease Spreading Fast in Sub-Saharan Africa, 
BOSTON GLOBE, June 15, 2002, at Al (stating that approximately twenty-three 
million people have died from the disease-far more than even Europe's Black Death 
in the fourteenth century); AIDS EPIDEMIC UPDATE 2002, supra note 2, at 5. 
6 AIDS EPIDEMIC UPDATE 2002, supra note 2, at 4. 
7 CENTERS FOR DISEASE CONTROL & PREVENTION, The Global HN and AIDS 
Epidemic, 2001, 50 MORBIDITY & MORTALITYWKLY. REP. 434,434 (2001). 
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Map 2: Adults and children estimated to be newly 
infected with HIV in 2002* 
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* Source: AIDS EPIDEMIC UPDATE 2002, supra note 2, at 34. 
5 
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The impact of HIV/AIDS is evident in regions around the 
world (See Table 1). The Mrican continent has experienced 
the greatest burden of disease. For example, in Botswana, 
the country which has the highest prevalence of HIV, 
almost forty percent of its adult population is infected.s The 
average life expectancy in Botswana is now below forty 
years for the first time since 1950.9 As a result of the AIDS 
epidemic, the average life expectancy in southern Africa is 
expected to drop to under thirty years of age by 201010 (See 
Figure 1). The fastest growing rate of HIV infection is in 
Russia.ll In Russia alone, HIV has increased fifteen-fold in 
the last three years.12 In China, the world's most populous 
country, the government acknowledged that 600,000 to one 
million people are living with HIV/AIDS; only four percent 
of the adults there, however, even know how HIV is 
contracted and spread. 13 
8 Liz McGregor, Botswana Battles Against 'Extinction,' THE GUARDIAN, July 8, 
2002, at 12. 
9 Id. 
10 KAREN A. STANECKI, U.S. CENSUS BUREAU, THE AIDS PANDEMIC IN THE 21ST 
CENTURY 11 (2002). 
11 AIDS EPIDEMIC UPDATE 2002, supra note 2, at 12. 
12 Id. 
13 Elisabeth Rosenthal, With Ignorance as the Fuel, AIDS Speeds Across China, 
N.Y. TIMES, Dec. 30, 2001, at AI. See Schwartlander, supra note 1, at 64. 
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Table 1: 
. Regional HIV/AIDS Statistics and Features* 
Region Epidemic Adults & Adults & Adult %of Main modes of 
Started Children Children Prevalence HIV- transmission for 
living with newly Rate positive those who are 
HIV/AIDS infected adults living with 
with who are HIV/AIDS** 
HIV/AIDS women 
Sub-Saharan late 70s 28.1 million 3.4 million 8.4% 55% Hetero 
Africa early 80s 
North Africa late 80s 440,000 80,000 0.2% 40% Hetero, IDU 
& 
Middle East 
South & late 80s 6.1 million 800,000 0.6% 35% Hetero, IDU 
South-East 
Asia 
East Asia & late 80s 1 million 270,000 0.1% 20% IDU, Hetero, 
Pacific MSM 
Latin late 70s 1.4 million 130,000 0.5% 30% MSM,IDU, 
America early 80s Hetero 
Caribbean late 70s 420,000 60,000 2.2% 50% Hetero, MSM 
early 80s 
Eastern early 90s 1 million 250,000 0.5% 20% IDU 
Europe & 
Central Asia 
Western late 70s 560,000 30,000 0.3% 25% MSM,IDU 
Europe early 80s 
North late 70s 940,000 45,000 0.6% 20% MSM,IDU, 
America early 80s Hetero 
Australia & late 70s 15,000 500 0.1% 10% MSM 
New Zealand early 80s 
TOTAL 40 million 5 million 1.2% 48% 
.. 
** Hetero = heterosexual transmIssIon; IDU= transmIsSIOn through mJecbon drug use; 
MSM= sexual transmission among men who have sex with men. 
* Source: AIDS EPIDEMIC UPDATE 2002, supra note 2, at 6. 
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Figure 1: 
Deaths from AIDS and People Using Antiretroviral Drugs* 
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drugs at end of 2001 
* Source: Robert Steinbrook, Beyond Barcelona-The Global Response, 347 NEW ENG. 
J. MED. 553, 553 (2002). 
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The epic tragedy of HIV I AIDS in Africa and the tragedy 
unfolding in other regions is exacerbated by "simultaneous 
catastrophes": famine and armed conflict.14 In Africa, the 
AIDS epidemic, coupled with famine,15 has sapped the 
strength and eroded the skills of land workers, retarded 
agricultural production, and reduced rural livelihoods. 16 
Additionally, people suffering from AIDS require more food. 
Nutritional requirements for entire communities have 
increased as a result of rampant HIV/AIDS infection.17 War 
and civil strife also contribute to the tragedy of AIDS. IS 
Populations at war are often subjected to human rights 
abuses, conditions of poverty and mass displacement. 19 One 
of the most prevalent human rights abuses in nations at 
war is sexual violence.2o Conditions of poverty might lead 
people to engage in commercial sex to survive. The massive 
displacements of people are associated with disruption of 
social cohesion and relationships, fostering promiscuity and 
commercial sex.21 Large population movements, moreover, 
facilitate the geographic spread ofHIV infection.22 
Societies are fundamentally altered as a result of 
HIV/AIDS penetrating through various populations: 
HIV/AIDS among young adults weakens the labor force and 
destabilizes the economy;23 HIV/AIDS among mothers and 
14 Kofi A. Annan, Editorial, In Africa, AIDS Has a Woman's Face, N.Y. TIMES, 
Dec. 29, 2002, § 4, at 9 (stating that millions of Mrican women are threatened by 
two simultaneous catastrophes: famine and AIDS). 
15 At least thirty million people are at risk of starvation in southern Africa and 
the Horn of Africa. Id. 
16 Id. 
17 Peter Piot, Editorial, Fighting Aids with a Sound Investment, WASH. POST, 
Nov. 27, 2002, atA17. 
18 AIDS EPIDEMIC UPDATE 2002, supra note 2, at 35. 
19 Id. 
20 See id. (noting that in the Balkan conflict, 30,000 to 40,000 women were 
raped). 
21 Id. (noting that almost ten percent of women who had been displaced as a 
result of armed conflict in Sierra Leone had been sexually assaulted). 
22 Anne Buve et al., The Spread and Effect of HN·l Infection in Sub-Saharan 
Africa, 359 LANCET 2011, 2015 (2002). 
23 Thomas C. Quinn, Global Burden of the HN Pandemic, 348 LANCET 99, 101 
HeinOnline -- 17 Emory Int’l L. Rev. 10 2003
10 EMORY INTERNATIONAL LAW REVIEW [Vol. 17 
fathers creates parentless children and dislocated families;24 
HIV/AIDS among infants and youth diminishes hope and 
possibilities for the future. 25 In short, the pandemic 
destroys families and social networks, diminishes economic 
growth, and creates a sense of pessimism about the future. 26 
The security of countries and regions is affected because 
HIV/AIDS can have a destabilizing effect on society. 
HIV/AIDS creates poverty, a sense of vulnerability and 
hopelessness that feeds conditions leading to feuds, 
violence, and dislocation. In turn, wars and armed conflict 
exacerbate conditions of poverty, powerlessness, and social 
instability, all of which facilitate HIV transmission.27 A 
healthier, more prosperous, and stable Third World would 
experience fewer conflicts and disasters.28 
In recognition of these substantial harms, the United 
States has declared HIV/AIDS a threat to national 
security.29 The strength of American sentiment was clear in 
the words of U.S. Secretary of State, Colin Powell, stating 
(1996). 
24 The orphan crisis has grown considerably, changing the landscape of the 
family, particularly in sub-Saharan Mrica. More than thirteen million children 
under age fifteen have lost one or both parents to AIDS. By 2010, this number is 
expected to grow to twenty-five million. Governments and international agencies 
have remained somewhat complacent in the face of this crisis, perhaps due to the 
traditional Mrican social system which has absorbed many of the most vulnerable 
children. UNAIDS, UNICEF, & U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT, 
CHILDREN ON THE BRINK 2002: A JOINT REPORT ON ORPHAN ESTIMATES AND 
PROGRAM STRATEGIES 3 (2002) [hereinafter CHILDREN ON THE BRINK); Geoff Foster, 
Supporting Community Efforts to Assist Orphans in Africa, 346 NEW ENG. J. MED. 
1907,1907 (2002). 
25 See CHILDREN ON THE BRINK, supra note 24, at 3. 
26 UNAIDS & WORLD BANK, HIV AND HUMAN DEVELOPMENT: THE DEVASTATING 
IMPACT OF AIDS (1998), at 6-7 [hereinafter HIV AND HUMAN DEVELOPMENT: THE 
DEVASTATING IMPACT OF AIDS); UNAIDS, GmDELINES FOR STUDIES OF THE SOCIAL 
AND ECONOMIC IMPACT OF HIV/AIDS, at 9 (2000), available at 
http://www.unaids.orglpublicationsldocuments/economicslcosteffeclJC326-Guidelines 
.pdf (last visited Apr. 7, 2003). 
27 AIDS EPIDEMIC UPDATE 2002, supra note 2, at 35. 
26 Editorial, Health Aid for Poor Countries, N.Y. TIMES, Jan. 3, 2002, at A22. 
29 Barton Gellman, AIDS is Declared Threat to Security, WASH. POST, Apr. 30, 
2000, at AI. 
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that: "I was a soldier and I know of no enemy in war more 
insidious or vicious than AIDS, an enemy that poses a clear 
and present danger to the world.,,30 
Prevention of HIV/AIDS would benefit all regions and 
countries, irrespective of the prevalence or incidence of 
HIV/AIDS in the population as all social and economic life 
in the early twenty-first century is interconnected. 
HIV/AIDS in one part of the world is bound to affect the 
health, economy, and security of countries everywhere. The 
health of all people is affected by modern travel and 
migration patterns. HIV/AIDS, and the interconnected 
epidemics of tuberculosis, sexually transmitted diseases, 
and drug dependency, can spread across countries and 
regions.31 The economy of all countries is affected because 
of the complex economic and trade relationships that exist 
within the modern world. Countries and regions with a 
heavy burden of HIV/AIDS often have weaker economies, 
impeding their ability to import and export essential 
products and services.32 This has a cascading effect on the 
economies of other countries. 
30 Colin Powell, Remarks at the United Nations General Assembly Special 
Session on HIV/AIDS: Opening Session, at 46 (June 25, 2001), available at 
http://www.kaisernetwork.orglhealth_castluploaded_fileslACF427.pdf (last visited 
Apr. 10,2003). 
31 Kevin M. De Cock & Robert S. Janssen, An Unequal Epidemic in an Unequal 
World, 288 JAMA 236, 237 (2002). 
32 See, e.g., INT'L LAB. ORG., HIV/AIDS IN AFRICA: THE IMPACT ON THE WORLD OF 
WORK (noting that deaths and disabilities caused by AIDS are eroding the workforce 
and estimating that in countries where AIDS incidence is greater than five percent, 
national income will be chilled), at http://www.ilo.org/public/english/protection 
Itrav/aidsldownload/pdf/adforange.pdf (last visited Mar. 18, 2003). 
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Given the undeniable global effects of HIV/AIDS, one 
might expect the international community to unite in an 
effort to reach the common goal of preventing and treating 
HIV/AIDS. In June 2001, the United Nations General 
Assembly adopted by consensus the Declaration of 
Commitment on HIV/AIDS: "Global Crisis-Global Action.,,a3 
In the Declaration, 189 governments pledged to reduce HIV 
prevalence among young people by twenty-five percent in 
the worst affected countries by 2005 and globall, by 2010.34 
International organizations, such as UNAIDS,3 the World 
Health Organization (WHO),36 and the World Bank,37 have 
also issued warnings and calls for action (See Figure 2). 
33 See generally DECLARATION OF COMMITMENT ON HIV/AIDS, UNITED NATIONS 
GENERAL AsSEMBLY SPECIAL SESSION ON HIV/AIDS (2001), available at 
http://www.unaids.orglUNGASS/docsiAIDSDeclaration_en.pdf (last visited Mar. 15, 
2003). 
34 See generally id. 
35 See AIDS EPIDEMIC UPDATE 2002, supra note 2 passim; HIV AND HUMAN 
DEVELOPMENT: THE DEVASTATING IMPACT OF AIDS, supra note 26, at 6-7; UNAIDS, 
GUIDELINES FOR STUDIES OF THE SOCIAL AND ECONOMIC IMPACT OF HIV/AIDS, 
supra note 26, at 9. 
36 See THE WORLD HEALTH ORGANIZATION, COMMISSION ON MACROECONOMICS 
AND HEALTH passim (2001). 
37 See WORLD BANK, CONFRONTING AIDS: PUBLIC PRIORITIES IN A GLOBAL 
EPIDEMIC passim (1997) [hereinafter CONFRONTING AIDS]. 
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Figure 2: The HIV/AIDS Epidemic Timeline* 
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13 
*Source: Adapted from timelines prepared by the Kaiser Foundation and American 
Medical Student Association 
Yet, the responses by governments to the HIV/AIDS 
pandemic have been fragmented. There is often an absence 
of political will, an unwillingness to share strategies and 
resources, and wide philosophical and pragmatic 
differences, principally among countries in the NorthlWest 
and those in the South/East.38 This unwillingness to 
cooperate is caused, in part, by insular attitudes toward 
world health, economics, and politics. There is a certain 
narrow self-interest that seems to prevent many countries 
from engaging in truly global cooperative approaches. The 
unwillingness to cooperate may also be due to the fact that 
resource-rich and resource-poor countries have markedly 
38 See De Cock & Janssen, supra note 31, at 237. 
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different priorities tailored to the different dynamics of the 
epidemic in their regions.39 
This Article examines the major social, political, 
economic, and ethical issues involved in the global HIV 
pandemic. First, it examines the steps needed to prevent 
and treat HIV effectively and examines why many leaders 
have not responded more forcefully. This Part discusses the 
intangible, but crucial, aspect of political will. 40 Second, this 
Article looks at the divisive issue of drugs, patents, and 
international trade law. Highly developed countries 
usually want to uphold the patent system to protect the 
proprietary interests of drug companies, which keeps the 
price ofHIV/AIDS drugs high, placing them out of the reach 
of resource-poor countries. Finally, this Article examines 
the vexing issue of research ethics. The research 
community has struggled with one overriding question in 
international collaborative investigations: Should the 
ethical standards held in developed countries apply when 
engaging in research in less developed countries? 
Stakeholders are at odds and struggle to find the balance 
between ensuring strong ethical standards and expediting 
access to cost-effective treatments in poor countries. 
I. SCIENCE, POLITICS, AND MONEY: UNDERSTANDING THE 
PROBLEM AND WORKING TOWARD A SOLUTION 
Individually, we must demonstrate the qualities of 
courage, integrity and respect for others. Collectively, 
our governments must recognize that leadership 
means abandoning rhetoric and taking action. They 
39 See Quinn, supra note 23 passim. 
40 CARMEN PEREZ-CASAS, HIV/AIDS MEDICINES PRICING REPORT 1 (2000), 
available at http://www.accessmed-sf.orgiuploadlReportsandPublications/ 
49200113585IDuban%20report%20update%20dec%202000.pdf (last visited Mar. 15, 
2003). 
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must energize our people and mobilize the necessary 
resources to conduct the campaign against HIV/AIDS. 
Gra'la Mackel, African Development Forum (2000). 
15 
National governments have unique responsibilities for 
preventing and treating HIV/AIDS and mitigating its public 
health and economic effects. Only governments have the 
means and mandate to provide for "public goods" services 
that benefit society but that the market will not provide due 
to insufficient incentives.41 The role of the government is to 
advance the well-being of its citizens and promote a fair 
distribution of social benefits. Governments, acting for the 
people, should adopt the most effective strategies and 
marshal the resources needed to reduce the burden of the 
epidemic. 
Most importantly, governments should act as soon as 
possible. As Dr. Peter Piot, UNAIDS Executive Director, 
told an audience at the Fourteenth International AIDS 
Conference, "It is now clear that the AIDS epidemic is still 
in its early stages. And let us be equally clear: our fight 
back is at an even earlier stage.,,42 Nearly half the world's 
population lives in areas where HIV is rare. 43 Investments 
in prevention and education at the earliest stages of an 
epidemic are the least expensive and most effective actions 
available to a government.44 Decisive action could have 
saved countless lives in populous countries such as India 45 
41 CONFRONTING Ams, supra note 37, at 40. 
42 Press Release, UNAIDS, UNAIDS Executive Director Says AIDS Battle Must 
be Fought on the Global Political Stage (July 7, 2002), available at 
http://www. unaids.orglwhatsnew/press/englpressarc02lBarcelona_070702.html (last 
visited Mar. 15, 2003). 
43 CONFRONTING AIDS, supra note 37, at 7. For example, the adult infection 
prevalence in North Mrica and the Middle East was 0.3 percent at the end of 2002 
and in East Asia and the Pacific, the proportion of infected adults was a mere 0.1 
percent. AIDS EPIDEMIC UPDATE 2002, supra note 2, at 6. 
44 CONFRONTING AIDS, supra note 37, at 7. 
45 Kevin M. De Cock & Helen A. Weiss, The Global Epidemiology of HNIAIDS, 
5 TROPICAL MED. & INT'L HEALTH A3, A8 (2000). 
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and South Mrica.46 It could still save lives in China, 
Russia, and other regions where poverty and lack of 
education lead to drug use and the spread of disease. 47 
The public health community has long agreed on the 
appropriate response to HIV/AIDS.4B For instance, unified 
strategies directed at youth focus on empowerment and 
education49 (See Table 2). While strategies vary according 
to local conditions and cultures, the need for surveillance, 
prevention, treatment, and protection of human rights are 
the same everywhere. 
Table 2: 
Ten Step Strategy for HIV Prevention Among Youth* 
1. End the Silence, Stigma and Shame 
2. Provide Young People with Knowledge and 
Information 
3. Equip Young People with Life Skills to Put 
Knowledge Into Practice 
4. Provide Youth-Friendly Health Services 
5. Promote Voluntary and Confidential HIV 
Counseling and Testing 
6. Work with Young People, Promote Their 
Participation 
7. Engage Young People Who are Living with 
HIV/AIDS 
8. Create Safe and Supportive Environments 
9. Reach Out to Young People Most At Risk 
10. Strengthen Partnerships, Monitor Progress 
*Source: UNICEF, UNAIDS & WHO, supra note 3, at 25-36. 
46 See generally Donald G. McNeil, Jr., AIDS and Death Hold No Sting for 
Fatalistic Men at African Bar, N.Y. TIMES, Nov. 29, 2001, at A14 (noting that 
"poverty and ignorance about health run so deep"). 
47 See Elisabeth Rosenthal, A Poor Ethnic Enclave in China is Shadowed by 
Drugs and HN, N.Y. TIMES, Dec. 21, 2001, at AI; Rosenthal, supra note 13. 
48 See, e.g., UNICEF, UNAIDS & WHO, supra note 3, at 25-36 (reprinted infra, 
tbl. 2) 
49 Id. 
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Public health authorities cannot develop the most 
appropriate policies for prevention and treatment without 
accurate data about the prevalence and incidence of 
HIV/AIDS in the general population and within specific 
communities.50 Through comprehensive screening, 
reporting, and active surveillance, policy makers can 
ascertain the scope and direction of the epidemic in their 
country. 51 Surveillance provides clear information about 
the growing burden of HIV/AIDS on women, youth, and 
ethnic minorities, and within groups at heightened risk in 
the society, such as homosexuals, injection drug users, and 
sex workers.52 The information gathered can then be used 
to assist groups most affected by the disease. 
Understanding the risks and realities of HIV/AIDS is a 
necessary precursor to behavior change.53 Accordingly, 
disseminating information to the public about health risks 
is vital. It is crucial that individuals understand the 
methods of contracting and transmitting HIV. This should 
include education, counseling, and other methods of 
targeted health promotion. Educational messages should 
target the specific needs of individuals and groups. AIDS 
education should be culturally and linguistically 
appropriate, but sufficiently explicit to convey the 
information clearly. 
Societal prohibitions must not thwart AIDS education. 
For example, educational materials targeted at gay men 
should not avoid a graphic discussion of risky behaviors as 
a concession to the wider population's moral beliefs. In 
certain communities, there may also be a pervasive culture 
50 See generally Lawrence O. Gostin et aI., National HN Case Reporting for the 
United States-A Defining Moment in the History of the Epidemic, 337 NEW. ENG. J. 
MED 1162, 1162-64 (1997). 
51 See id. at 1163-64. 
52 [d. at 1163. 
53 See generally THE WORLD BANK, EDUCATION AND HIVIAIDS, A WINDOW OF 
HOPE xvii, 5 (2002) (noting that education is a "proven means to prevent 
HIV/AIDS"), available at http://wwwl.worldbank.org/education/pdflEd%20&%20 
HIV _AIDS% 20cover%20print.pdf (last visited Mar. 20, 2003). 
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of silence that excludes discussion of HIV/AIDS. A brave 
action to break this silence took place at the Thirteenth 
International AIDS Conference in Durban, South Mrica, 
where Nkosi Johnson, a boy living with HIV/AIDS, 
criticized his President for neglecting the epidemic in South 
Mrica.54 Advocates and role models like Johnson are 
instrumental in raising awareness about HIV/AIDS and 
highlighting government denial of the true facts of the 
epidemic. 
Even when the risks of certain behaviors may be 
understood, eliminating risky activity is not always possible 
or realistic. While experience demonstrates that 
prohibition messages (e.g., ''just say no") are not effective 
because individuals will continue to engage in risky 
behaviors,55 harm reduction strategies have been shown to 
be effective in reducing risky behaviors.56 Harm reduction 
strategies are those that provide individuals at risk with 
the means to protect themselves, such as condoms or sterile 
drug injection equipment.57 
The public health strategies discussed above are 
insufficient to reduce the burden of HIV/AIDS unless people 
are empowered to protect their health. One of the primary 
strategies in the fight against HIV/AIDS is to safeguard the 
human rights of those who are at risk of infection or are 
infected. Girls and women are especially vulnerable. While 
they may understand the risks and have access to condoms, 
.4 Belinda Beresford, Nkosi Johnson: Child Who Became the Campaigning Face 
of AIDS in South Africa, THE GUARDIAN, June 2, 2001, at 22, available at 
http://www.guardian.co.ukJaidslstory/0,7369,500309,00.html (last visited Mar. 15, 
2003). 
55 Douglas Kirby, Do Abstinence-Only Programs Delay the Initiation of Sex 
Among Young People and Reduce Teen Pregnancy? NAT'L CAMPAIGN TO PREVENT 
TEEN PREGNANCY 5 (2002) available at http://www.teenpregnancy.org/ 
resources/datalpdf7abstinence_eval.pdf(last visited Apr. 5, 2003). 
56 See Scott Burris et aI., Harm Reduction in the Health Care System: The 
Legality of Prescribing and Dispensing Syringes to Drug Users, 11 HEALTH MATRIX 
5, 12-13 (2001). 
57 See generally id. at 5-7. 
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they may not be able to control safer sex practices.58 
Women's relationships may be controlled by violence, 
cultural expectations, or economic dependence. When a 
woman's husband leaves her or dies, women may be 
deprived of credit, distribution networks, or land rights.59 
Improving the status of women and strengthening their 
social, political, and economic rights would allow them to 
protect themselves against HIV and other health threats.6o 
Because prevention of HIV infection is not always 
possible, government policies should address both 
prevention and post-infection health care. Individuals can 
lead healthier and longer lives if they receive treatment for 
HIV.61 Health care can alleviate symptoms and reduce the 
likelihood of opportunistic infections. As President William 
J. Clinton observed, "[h]istorians will look back on our time 
and see that our civilization spends many millions of dollars 
educating people about the scourge of H.I.V. . .. But what 
they will find not so civilized is our failure to treat ninety-
five percent of people with the disease.,,62 In July 2002, the 
United Nations High Commissioner for Human Rights 
(UNHCHR) and UNAIDS developed updated guidelines on 
HIV/AIDS and human rights, which declared that access to 
HIV/AIDS treatment is fundamental to realizing the right 
to health and that access to medication is one element of a 
comprehensive program of prevention, treatment, care, and 
support.63 
58 See generally Donald G. McNeil, Jr., Rare Condoms, Deadly Odds for Truck-
Stop Prostitutes, N.Y. TIMES, Nov. 29, 2001, at A14. 
59 Annan, supra note 14, § 4, at 9. 
60 See Quinn, supra note 23, at 101, 105. 
61 CENTERS FOR DISEASE CONTROL AND PREVENTION, NATIONAL AIDS 
SURVEILLANCE DATA 2, available at http://www.cdc.gov/hiv/graphics/images/ 
12851l285-6.pdf (last visited Apr. 10, 2003); J.T. King, Jr. et al., Long-Term 
HN I AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era, 23 
MED. DECISION MAKING 9 (2003). 
62 William Jefferson Clinton, AIDS is Not a Death Sentence, N.Y. TIMES, Dec. 1, 
2002, at D9. 
63 See Office of the U.N. High Comm'r for Human Rights & the Joint U.N. 
Programme on HIV/AIDS, HNIAIDS and Human Rights Guidelines 6 (2002), at 13, 
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A. The Impact of Political Will 
"Above all, the challenge of AIDS is a test of leadership.,,64 
The strategies for prevention and treatment of HIV/AIDS 
are well accepted and have been used in practice in 
countries as varied as Senegal, Thailand, Uganda, Brazil, 
Zambia, and Cambodia. For example, Uganda, with limited 
access to high technology medicine, has reduced the 
average national prevalence of HIV among adults from 
around 18.5% in 1995 to 8.3% at the end of 1999.65 The 
government of Uganda's response to the epidemic dates 
back to 1986 when the first AIDS Control Programme was 
created in the Ministry of Health.66 The Uganda AIDS 
Commission (UAC) was instituted in 1992 and placed under 
the Office of the President.67 The UAC created an 
atmosphere of openness and effective political commitment 
to HIV/AIDS control which has created high levels of public 
awareness about the dangers of the epidemic and means of 
t · 68 preven IOn. 
A similar picture of success can be found in Senegal 
where the government acted rapidly to develop a national 
program to prevent HIV, beginning with systematic blood-
screening in 1986.69 The government in Dakar, Senegal was 
HRlPUB/2002/1 (2002). 
64 Kofi A. Annan, The Secretary-General Address to the Mrican Development 
Forum in Addis Ababa, (Dec. 7, 2000), available at http://www.uneca.orgl 
adf2000/daily_updates/speeches_and_press_releases/120700address_kofi_annan.htm 
(last visited Mar. 15, 2003). 
65 UGANDA AIDS COMM'N, TwENTY YEARS OF HIVIAIDS IN THE WORLD: 
EVOLUTION OF THE EPIDEMIC AND RESPONSE IN UGANDA 2 (2001), available at 
http://www.aidsuganda.orgl20%20years%20of%20HIV.pdf !hereinafter EPIDEMIC 
AND RESPONSE IN UGANDA]; Uganda AIDS Comm'n, National Documentation Center 
(NADIC), Mandate and Background, at http://www.aidsuganda.orgluac.htm (last 
visited Mar. 15, 2003). 
66 EPIDEMIC AND RESPONSE IN UGANDA, supra note 65, at 3. 
67 See id.; Helen Epstein,AIDS: The Lesson of Uganda, N.Y. REv. BOOKS, July 5, 
2001, at 18. 
68 See generally EPIDEMIC AND RESPONSE IN UGANDA, supra note 65. 
69 Mamadou Mika Lorn, Senegal's Recipe for Success, 15 AFRICA RECOVERY 24, 
24 (2001), available at http://www.un.orglecosocdev/geninfo/afreclvo115no1l15no1pdfl 
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the driving force behind a declaration on AIDS made by 
heads of member states of the Organization of African 
Unity in June 1992.70 Senegal invested significant 
resources in the mid-1990s to increase AIDS awareness.71 
In the late 1990s, over ninety percent of the general 
population in Senegal knew about HIV and methods of 
prevention.72 
Although both Uganda and Senegal represent success 
stories in the AIDS epidemic, governments rarely 
implement proven public health strategies due to an 
absence of committed political leadership and inadequate 
funding. Despite the epidemic's potential impact on the 
health and the economy of a country, many national leaders 
demonstrate a benign neglect of the epidemic.73 The 
reasons are complex. HIV/AIDS is perceived to interfere 
with other Rriorities such as national image, tourism, and 
even trade. 4 As HIV/AIDS is associated with unlawful or 
stigmatized behaviors such as drug use, homosexuality, and 
promiscuous heterosexuality, some political leaders seek to 
deemphasize its prevalence in society.75 This absence of 
151aidl1.pdf (last visited Mar. 15,2003). 
70 Organization of African Unity, Decisions and Resolutions Adopted by the 28th 
Ordinary Session of the Assembly of Heads of State and Government, AHG/Res. 206 
(XXVIII) at 16, available at http://www.iss.co.za/AF/RegOrg/unity_to_unionJpdfsl 
oaulhogl2HoGAssemblyl992.pdf (last visited Apr. 14, 2003). 
71 Nicolas Meda et aI., Low and Stable HN Infection Rates in Senegal: Natural 
Course of Epidemic or Evidence for Success of Prevention? 13 AIDS 1397, 1402 
(1999). 
72 UNAIDS, ACTING EARLY TO PREVENT AIDS: THE CASE OF 
SENEGAL 17 (1999), available at http://www.unaids.org/publications/documents/ 
epidemiology/determinants/una9ge34.pdf (last visited Apr. 14,2003). 
73 J.M. Spectar, The Hybrid Horseman of the Apocalypse: The Global AIDS 
Pandemic and the North-South Fracas, 29 GA. J. INT'L & COMPo L. 253, 273 (2001); 
Rosie DeManno, Old Warrior Mandela Brings Moral Weight to Fight Against AIDS, 
TORONTO STAR, July 13, 2002 at A27. 
74 See Audrey R. Chapman, Conceptualizing the Right to Health: A Violations 
Approach, 65 TENN. L. REV. 389, 402 (1998) (noting that some countries withheld 
statistics regarding HIV incidence to avoid discouraging tourism or stigmatizing the 
country's image). 
75 LAWRENCE O. GOSTIN & ZITA LAzZARINI, HUMAN RIGHTS AND PUBLIC HEALTH 
IN THE AIDS PANDEMIC 53 (1997). 
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political leadership occurs irrespective of culture or region. 
Political inaction was as evident in the United States in the 
1980s and in Kenya and Zimbabwe in the 1990s as it is in 
India and China today.76 The politics of AIDS are complex 
and dependent on resources, culture, experience, and 
perception. The type of health care offered by nations 
closely correlates with available resources. Resource-poor 
countries generally focus their efforts on education and 
basic medical treatment. More developed countries 
commonly offer sophisticated treatments, including 
antiretroviral therapy and treatment of symptoms, which 
stabilize the levels ofHIV.77 
Political leaders must have discretion to allocate 
resources according to the most pressing needs in a country. 
HIV/AIDS is not always the single greatest need. Poor 
countries have urgent requirements for education, 
transportation, sanitation, security, and other necessities. 
Major threats are posed to the population from violence, 
dislocation, and infectious diseases such as malaria and 
tuberculosis. Spending substantial sums of money on high 
technology HIV medications, for example, may not save the 
most lives given scarce resources. But political leaders 
should recognize the current or potential devastation of 
HIV/AIDS. There is never an excuse to ignore or 
underestimate the scope and impact of the pandemic. Basic 
AIDS education, prevention, and treatment can help 
produce the conditions in which people can lead healthy 
lives. 
South African President Thabo Mbeki exemplifies the 
inaction of some leaders. Mbeki has questioned whether 
76 Maureen Dowd, Dr. Koop Defends His Crusade on AIDS, WASH. POST, Apr. 6, 
1987, at B8; Susan Okie, AIDS Devouring Africa Even as Awareness Grows, WASH. 
POST, Apr. 18, 1994, at AI; M. Taegtmeyer & K. Chebet, Overcoming Challenges to 
the Implementation of Antiretroviral Therapy in Kenya, 2 LANCET INFECT. DIS. 51,51 
(2002). 
77 News Release, National Institutes of Health, New Model Suggests that AIDS 
Drugs May Not Abolish HIV Infection (Oct. 6, 1999), available at 
http://www.nih.gov/news/pr/oct99/niaid·06a.htm (last visited Mar. 15,2003). 
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HIV actually causes disease, stating, "[y]ou cannot attribute 
immune deficiency solely and exclusively to a virus.,,78 Such 
skepticism of science by a respected poli tical leader 
seriously undermines AIDS education and prevention. 
President Mbeki has also openly doubted the accuracy of 
his own Department of Health estimates of the national 
HIV prevalence among pregnant women. The data, based 
on annual unlinked, anonymous HIV surveys among 
women attending antenatal clinics, demonstrate a thirty-
fold increase in HIV prevalence-from 0.7% in 1990 to 
22.4% in 1999.79 For several years, the Ministry of Health, 
under President Mbeki resisted full implementation of 
UNAIDS guidelines for short-course antiretroviral therapy 
for pregnant women,80 even though it had been 
demonstrated to be cost effective in South Mrica.81 
Fortunately, there have been competing voices about the 
dangers of political inaction from the African National 
Congress. Former South African President Nelson Mandela 
observed: "N othing threatens us more today than 
78 Mbeki: HN Not Only Cause of AIDS, AsSOCIATED PRESS, Sept. 10, 2000, at 
http://www.aegis.com/news/ap/2000/AP000905.html (last visited Mar. 15, 2003); 
South Africa and AIDS: Reason Prevails, ECONOMIST, Apr. 27, 2002, at 81 (noting 
that on April 24, 2002, Mr. Mbeki made his strongest statement yet that people 
must change their sexual behavior: "You can't be going around having hugely 
promiscuous sex all over the place and hope that you won't be affected."). 
79 Department of Health of the Republic of South Mrica, The HN Epidemic in 
South Africa (Feb. 2001), at http://www.uct.ac.zaldeptsimmiljmoodie/ancO.html (last 
visited Mar. 15, 2003). 
80 See Jimmy Volmink et aI., Reducing Mother-to-Child Transmission of HN 
Infection in South Africa, in INFORMING JUDGMENT: CASE STUDIES OF HEALTH 
POLICY AND RESEARCH IN SIX COUNTRIES 174, 179-81 (2001) (stating that UNAIDS 
has criticized laws that restrict access of antiretroviral drugs to the poor); WORLD 
HEALTH ORG., PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV: 
SELECTION AND USE OF NEVIRAPINE (2001) (noting that nevirapine, an 
antiretroviral drug, should be on the national list of essential drugs according to 
Interagency Guidelines for Drug Donations of the WHO), available at 
http://www.who.intidocstoreihivIPMTCT/ who_hiv_aids_2001.03.pdf 11 (last visited 
Mar. 15, 2003). 
81 Neil Soderlund et aI., Prevention of Vertical Transmission of HN: Analysis of 
Cost Effectiveness of Options Available in South Africa, 318 BRIT. MED. J. 1650, 1654 
(1999). 
HeinOnline -- 17 Emory Int’l L. Rev. 24 2003
24 EMORY INTERNATIONAL LAW REVIEW [Vol. 17 
HIV/AIDS. AIDS is a scourge threatening to undo all the 
gains we made in our generations of struggle.,,82 More 
radically, the Premier of KwaZulu-Natal, the South Mrican 
province most affected by HIV/AIDS, declared that he 
would distribute drugs to pregnant women with AIDS, in 
direct violation of central government policy.83 Further, the 
Constitutional Court of South Mrica drastically altered 
government policy in the 2002 court case, Minister of 
Health and Others v. Treatment Action Campaign and 
Others (TAC), when it upheld a request by TAC to provide 
nevirapine, an antiretroviral drug available to the 
government free of charge, to pregnant mothers at public 
hospitals.84 
B. The Impact of Economic Assistance 
Even with the political will, the least developed countries 
still need economic assistance for HIV prevention and 
treatment.85 Public health strategies require resources and 
man~ countries in the South and East cannot afford the 
cost. 6 Countries in the North and West have not made the 
political and economic commitment to international aid that 
is necessary to reduce the global burden of the disease.87 
There are compelling reasons to provide this kind of 
international assistance. The most fundamental reason is 
humanitarianism, the understanding that preventing 
82 Shifting Stance, Beijing Shows Drama on AIDS, N.Y. TIMES, Dec. 2, 2001, at 
A22. 
83 Rachel L. Swarns, A Bold Move on AIDS in South Africa, N.Y. TIMES, Feb. 5, 
2002, at AlO. 
84 Minister of Health and Others v. Treatment Action Campaign and Others, 
2002 (10) BCLR 1033 (CC) 'II 4 n.5, 135, available at http://www.concourt.gov.za/ 
judgments/2002ltac.pdfOast visited Mar. 15,2003). 
85 B. Schwartlander et al., Resource Needs for HNIAIDS, 292 SCI. 2434, 2434 
(2001). 
86 See id. at 2434-36. 
87 See Paul Blustein, Bush to Announce Three-Year AIDS Spending Initiative, 
WASH. POST, June 19, 2002, at A3 (noting that commitments have "fallen short" of 
Secretary General Kofi Annan's goal of $10 billion a year). 
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suffering and promoting human welfare is a reward in 
itself. Countries may also be motivated by their own self-
interest, because HIV/AIDS in the developing world deeply 
affects the health, economy, and security of people on a 
global scale. 
In the world's least developed countries, the average 
annual per capita health expenditure is $1688 compared to 
$4600 in the United States.8 The WHO recommends that, 
at a minimum, this should rise to $34.90 Consequently, the 
United Nations established a general fund to fight AIDS, 
Tuberculosis and Malaria to promote both prevention and 
treatment of these diseases,91 which account for ten percent 
of deaths worldwide.92 Although the United Nations 
Secretary General Kofi Annan announced that this fund 
needs $7-$10 billion a year for AIDS alone,93 donors pledged 
only $1.5 billion in 200194 and funding diminished further in 
the aftermath of the events on September 11, 2001.95 By 
88 U.N. CONFERENCE ON TRADE & DEVELOPMENT, THIRD U.N. CONFERENCE ON 
THE LEAST DEVELOPED COUNTRIES, HOSTED BY THE EUROPEAN UNION AND THE 
EUROPEAN PARLIAMENT IN BRUSSELS, BELGIUM 17 (2001), available at 
http://www.epe.be/objective2002l2ndconference/related/program.pdf (last visited 
Mar. 15, 2003). 
89 News Release, Organisation for Economic Development, OECD Health Data 
2002 (June 24, 2002) (citing health care statistics per capita in 2000), available at 
http://www .oecd.org/EN/documentlO"EN -document-O-nodirectorate-no-12-31 070,00. 
html (last visited Mar. 15, 2003). 
90 WORLD HEALTH ORG. COMM'N ON MACROECONOMICS & HEALTH, 
MACROECONOMICS AND HEALTH: INVESTING IN HEALTH FOR ECONOMIC 
DEVELOPMENT 11-12, 54,121 (2001), available at http://www.un.orglesalcoordination 
lecosocldocslRT.K.MacroeconomicsHealth.pdf (last visited Mar. 15,2003). 
91 The Global Fund to Fight AIDS, Tuberculosis & Malaria, Overview, at 
http://www.globalfundatm.orgloverview.html (last visited Feb. 23, 2003). 
92 Anders Nordstrom, Global Fund for AIDS, Tuberculosis and Malaria, 359 
LANCET 1621, 1622 (2002). See also WORLD HEALTH ORG., WORLD HEALTH REPORT 
2002, at 186, available at http://www.who.intlwhr/2002lwhr2002_annex2.pdf (last 
visited Apr. 10, 2003). 
93 Editorial, The Global Fund Confronts AIDS, N.Y. TIMES, Dec. 13, 2001, at 
A38. 
9. [d. 
96 Sarah Boseley, AIDS Bigger Problem Than Terrorism, THE GUARDIAN, Dec. 
14, 2001, at 6, (noting that since September 11 to date of article, "only $2,000 has 
come in" for the Global Fund on HIVIAIDS), available at 
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the time of the Fourteenth International AIDS Conference 
in Barcelona in the summer of 2002, the Fund reached only 
about $2.8 billion.96 
President George W. Bush surprised many when he 
recently announced his Emergency Plan for AIDS Relief, in 
which he committed $15 billion over the next five years, 
including $10 billion in new funds, to combat the global 
AIDS crisis in fourteen countries in Mrica and the 
Caribbean.97 Although the details of the plan, which have 
to be approved by Congress, have not been fully disclosed, 
$1 billion of the additional $10 billion is earmarked for the 
Global AIDS Fund ("the Fund,,).98 Amplifying Bush's 
support for the Fund, the President also announced that 
Tommy Thompson, Secretary of the U.S. Department of 
Health and Human Services, is slated to become the 
chairman of the Fund.99 However, although appreciative, 
critics still contend that more money is necessary in order 
for the Fund to achieve its objectives. lOo Moreover, the 
President's decision to earmark such a small proportion of 
the new funding to the Global AIDS Fund underlines the 
Administration's preference for unilateral solutions, which 
is likely to lead to less efficient use of the money.lOl 
http://www.guardian.co.uk/aids/story/0,7369,618493,00. html (last visited Mar. 15, 
2003). 
96 PRIYA ALAGIRI ET AL., GLOBAL SPENDING ON HIV/AIDS IN RESOURCE-POOR 
SETTINGS 1, 4 (2002), available at http://www.kif.org/contentJ2002l604416044v2.pdf 
(last visited Mar. 15, 2003). 
97 Fact Sheet, U.S. Department of State, International Information Programs, 
White House Outlines Bush HN/AIDS Programs for Africa, Jan. 29, 2003, at 
http://usinfo.state.gov/regionaVaf/usafr/a3012901.htm (last visited Mar. 15,2003). 
98 Id. (noting that the remainder will be directed towards treatment and 
prevention programs including supplying anti-retroviral drugs for two million 
peoEle). 
David Brown, U.S. Official in Line to Lead Global Fund, WASH. POST, Jan. 31, 
2003, at A2. 
100 See id. 
101 See Sheryl G. Stolberg & Richard W. Stevenson, Bush AIDS Effort Surprises 
Many, But Advisers Call It Long Planned, N.Y. TIMES, Jan. 30, 2003, at Al (noting 
that advocates "complain that the money will not be parceled out quickly enough 
and that areas of the world where the epidemic is exploding, including China and 
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The need for donor funding is even more acute when one 
takes into account all health problems (beyond HIV/AIDS) 
in resource-poor countries. The WHO's Commission on 
Macroeconomics and Health estimated that to improve 
global health substantially, total donor funding to all low 
income countries would have to increase from current levels 
of approximately $6 billion to $27 billion by 2007.102 The 
Commission estimates that the increased funding could 
save eight million lives annually by 2010.103 
II. PHARMACEUTICALS, INTELLECTUAL PROPERTY, AND 
INTERNATIONAL TRADE 
Basic forms of HIV education, prevention, and treatment 
do not require sophisticated technologies. Most countries 
have the capacity to implement these public health 
strategies with little economic and technical assistance. As 
explained above, comprehensive prevention programs in 
Senegal, Uganda, and other countries have significantly 
reduced the prevalence of HIV or kept HIV prevalence 
low. 104 However, more advanced treatments for HIV, such 
as highly active antiretroviral therapy (HAART) , 105 as well 
as future vaccines, are vital for a complete response to the 
epidemic. Antiretroviral therapies not only enhance the 
lives of individuals, but also promote the public's health. 
Individuals who are in antiretroviral treatment, with low 
viral loads, are less likely to transmit the infection to sexual 
or needle-sharing partners or to newborns through 
India, are being ignored"); Editorial, A Serious Response to AIDS, N.Y. TIMES, Feb. 
1, 2003, at A1S. 
102 WORLD HEALTH ORG. COMM'N ON MACROECONOMICS & HEALTH, supra note 
90, at 11, 92. 
103 Id. at 11. 
104 STANECKI, supra note 10, at 2. 
105 Paul Farmer et aI., Community·Based Treatment of Advanced HN Disease: 
Introducing DOT·HAART (Directly Observed Therapy with Highly Active 
Antiretroviral Therapy), 79 BULL. WORLD HEALTH ORG. 1145, 1146 (2001) 
(explaining that the use of highly active antiretroviral therapy (HAART) has 
reduced the mortality of AIDS in North America and Europe). 
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childbirth or breast feeding. 106 Treatment, therefore, is 
clinically beneficial to individuals and a valuable 
component of a comprehensive HIV prevention program. 
More advanced treatments for HIV, however, are highly 
technical and prohibitively expensive for poorer countries. 
Very few people living with HIV/AIDS in resource-poor 
settings are receiving drug therapy, such as HAART.l07 
Arguments against the use of HAART in resource-poor 
countries have been based on the high cost of medications 
and the lack of infrastructure, necessary for using them 
properly. lOB 
Should the most modern HIV treatments be available to 
people irrespective of the country in which they live? There 
is a moral argument that a child or adult in a poorer 
country is entitled to life-prolonging medications. If a 
highly effective treatment such as antiretroviral therapy is 
available and commonly used in developed countries, there 
is a valid argument that this treatment should also be 
accessible in less developed countries. The benefits of 
treatment are no less clear and the lives of people in Africa 
or Asia are no less important than those in North America 
and Europe. 
The problem is that resource-poor countries cannot afford 
adequate health care. The difficulties are deeply rooted in a 
combination of household poverty, inadequate publicly-
supported health care, and the high price of essential 
medicines. Consider the fact that the cost of wholesale 
combination HIV therapy in the United States ranges from 
$2,500 to $8,000 per patient per year/09 while the average 
106 See Mina Hosseinipour et aI., Can Antiretroviral Therapy Be Used to Prevent. 
Sexual Transmission of Human Immunodeficiency Virus Type 1? 34 CLINICAL 
INFECTIOUS DISEASES 1391, 1392-94 (2002). 
107 AIDS EPIDEMIC 2002, supra note 2, at 22-39 (noting that of 38.5 million 
individuals affected with HIVIAIDS in developing countries, only 230,000 
individuals are receiving anti-retroviral therapy). 
108 Farmer, supra note 105, at 1149. 
109 Kenneth A. Freedberg, M.D. et aI., The Cost Effectiveness of Combination 
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per capita health expenditure in the least developed 
countries, as explained earlier, is only $16.110 
Tragically, high infection rates are found in countries 
least able to cope with the financial burden of providing 
health care. For example, in 2002, Zimbabwe had an 
estimated adult HIV infection prevalence of 33.7% and an 
economy generating a per capita Gross National Income 
(GNI) of only $530.111 Mozambique's HIV adult infection 
rate was thirteen percent with a GNI per capita of $220.112 
By contrast, Germany had an adult infection rate of 0.10% 
for the equivalent period and an economy generating a per 
capita GNI of $25,620.113 Obvious consequences flow from 
these figures about a country's ability to provide expensive 
treatments for its citizens. Further, if governments are not 
equipped to provide modern therapies, individuals residing 
in these poor countries are even less able to attain these 
therapies. Personal wealth is very low and health 
insurance of any kind is scarce. 114 For example, at the end 
of 2001, while an estimated four million South Mricans 
were infected with HIV, only 0.25% (i.e., ten thousand) had 
the personal resources to pay for treatments. 115 
Antiretroviral Therapy for HN Disease, 344 NEW ENG. J. MED. 824, 824 (2001). 
110 U.N. CONFERENCE ON TRADE & DEVELOPMENT, supra note 88, at 17. 
111 UNAIDSIWHO WORKING GROUP ON GLOBAL HIVIAIDS & STI SURVEILLANCE, 
ZIMBABWE: EPIDEMIOLOGICAL FACT SHEET ON HIVIAIDS AND SEXUALLY 
TRANSMITTED INFECTIONS 2, 3 (2002), available at http://www.who.intlemc-hiv/ 
fact_sheetslpdfs/Zimbabwe_EN.pdf(last visited Mar. 15,2003). 
112 UNAIDSIWHO WORKING GROUP ON GLOBAL HIV/AIDS & STI SURVEILLANCE, 
MOZAMBIQUE: EPIDEMIOLOGICAL FACT SHEET ON HIV/AIDS AND SEXUALLY 
TRANSMITTED INFECTIONS 2, 3 (2002), available at http://www.who.intlemc-
hiv/fact_sheets/pdfslMozambique_EN.pdf(last visited Mar. 15,2003). 
113 UNAIDSIWHO WORKING GROUP ON GLOBAL HIV/AIDS & STI SURVEILLANCE, 
GERMANY: EPIDEMIOLOGICAL FACT SHEET ON HIV/AIDS AND SEXUALLY 
TRANSMITTED INFECTIONS 2, 3 (2002), available at http://www.who.intlemc-
hiv/fact_sheetslpdfslGermany_EN.pdf (last visited Mar. 15, 2003). 
114 OXFAM, CUT THE COST PATENT INJUSTICE: How WORLD TRADE RULES 
THREATEN THE HEALTH OF POOR PEOPLE 3 (2001), available at 
http://www.oxfam.org.uklcutthecostldownloads/patent.pdf (last visited Mar. 15, 
2003) !hereinafter CUT THE COST PATENT INJUSTICE). 
115 Beresford, supra note 54, at 22. 
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International agencies ,116 non-governmental 
organizations,117 and AIDS activists118 have drawn attention 
to the urgent need for dramatically increased availability of 
medications in developing countries. They have 
concentrated, moreover, on the high price of therapy, which 
is perceived as the major barrier to access. 119 For example, 
the United Nations conducts a program of "Accelerated 
Access" in collaboration with five pharmaceutical 
companies. 120 The program assists countries with 
implementing comprehensive packages of care, treatment, 
and support for their citizens living with HIV/AIDS, 
including advocacy for significantly reduced drug prices. 121 
A. Patent Protection and the Artificially High Price of AIDS 
Medications 
Pharmaceutical companies, supported by advanced 
industrialized countries, often seek to maintain a high price 
for HIV medications. 122 These largely northern-based 
transnational companies claim that a market price is 
necessary to recoup the substantial costs of research and 
development. 123 The pharmaceutical sector argues that 
intellectual property protection stimulates investment and 
innovation. Failure to safeguard commercial interests, they 
116 UNAIDS, ACCELERATING ACCESS TO HIV CARE, SUPPORT AND TREATMENT 
(2001), at http://www.unaids.orglacc_access (last visited Feb. 6, 2003). 
117 CUT THE COST PATENT INJUSTICE, supra note 114, at 3. 
118 Bernard Pecoul et aI., Access to Essential Drugs in Poor Countries: A Lost 
Battle?, 281 JAMA 361,366-67 (1999). 
119 CUT THE COST PATENT INJUSTICE, supra note 114, at 5. 
120 UNAIDS, ACCELERATING ACCESS TO HIV CARE, SUPPORT AND TREATMENT, 
supra note 116. 
121 Id. 
122 OXFAM, Brazil Fights for Affordable Drugs Against HNIAIDS, 9 PAN. AM. J. 
PuBLIC HEALTH 331, 335-36 (2001), available at http://www.paho.org/EnglishlDBII 
es/v9n5-TEMA-BraziI.pdf (last visited Apr. 12, 2003) [hereinafter BRAZIL FIGHTS 
FOR AFFORDABLE DRUGS]. 
123 See, e.g., Sara Fritz, It's Time to Guarantee Same Drug Prices For All, ST. 
PETERSBURG TIMES (Fla.), May 1, 2000, at 1A. 
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suggest, would chill entrepreneurs and provide 
disincentives for inventors. 
The international trade system is specifically designed to 
safeguard the proprietary interests of corporations. There 
are basically three levels of international trade agreements: 
bilateral relationships (e.g., Canada-United States Free 
Trade Agreement), regional agreements (e.g., North 
America Free Trade Agreement (NAFTA», and multilateral 
arrangements (e.g., World Trade Organization/General 
Agreement on Tariffs and Trade (WTO/GATT». The 
defense of intellectual property is embedded in each level, 
making it difficult for developing countries to violate 
patents without the imposition of trade sanctions.124 
The WTO's agreement on Trade Related Intellectual 
Property Rights (TRIPS) establishes minimum standards 
for intellectual property protection, including the right to 
exclusively market a patented product for a minimum of 
twenty years. 125 Northern governments use bilateral and 
regional trade agreements to negotiate even more stringent 
protection for patents under so-called "TRIPS Plus" 
agreements.126 By restricting the right of governments to 
allow the production, marketing, and import of low cost 
copies of patented medicines (i.e., generic drugs), 
international trade rules restrict competition, increase 
prices, and further reduce the already limited access of poor 
people to vital medicines. 127 Patented HIV medicines 
typically cost between three and fifteen times as much as 
12. BRAZIL FIGHTS FOR AFFORDABLE DRUGS, supra note 122, at 333. 
125 WORLD TRADE ORG., TRADING INTO THE FUTURE 27 (2d ed. 2001) (noting that 
TRIPS provides the exclusive right to market a patented product for at least 20 
years), available at http://www.wto.orglenglishlres_eJdoload_e/tif.pdf (last visited 
Mar. 15, 2003). 
126 See, e.g., Simon Barber, Stars and Stripes-To Whom are the Battle of Seattle 
NOOs Accountable?, BUSINESS DAY (South Africa), Jan. 20, 2000, at 2. 
127 See Winston P. Nagen, International Intellectual Property, Access to Health 
Care, and Human Rights: South Africa v. United States, 14 FLA. J. INT'L. L. 155, 
162-63 (2002) (examining the extent to which international agreements limit access 
to essential drugs). 
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their generic equivalents. l28 Although there are relativel~ 
few patents for HIV medicines currently in force in Africa, I 9 
international trade rules will militate against the 
availability and affordability of AIDS treatments in the 
future. 13o 
The United States and other developed countries argue 
for the "harmonization" of intellectual property rules with 
the goal of conforming the Ratent laws of least developed 
countries to their own. l 1 Proponents argue that 
harmonization of strong patent laws facilitates rapid 
economic development of poor countries through increased 
trade and foreign investment.132 Indeed, Article 7 of TRIPS 
states that: 
The protection and enforcement of intellectual property 
rights should contribute to the promotion of 
technological innovation and to the transfer and 
dissemination of technology, to the mutual advantage 
of producers and users of technological knowledge and 
in a manner conducive to social and economic welfare, 
and to a balance of rights and obligations.133 
In contrast, least developed countries typically resist 
harmonization and perceive the process as harmful to their 
interests. 134 As these countries often lack a scientific 
128 CUT THE COST PATENT INJUSTICE, supra note 114, at 4. 
129 Amir Attaran & Lee Gillespie-White, Do Patents for Antiretroviral Drugs 
Constrain Access to AIDS Treatment in Africa?, 286 JAMA 1886, 1887 (2001). 
130 CUT THE COST PATENT INJUSTICE, supra note 114, at 3-4. 
131 See Kate H. Murashige, Harmonization of Patent Laws, 16 Hous. J. INT'L L. 
591,597,606 (1994). 
132 Keith E. Maskus, Intellectual Property Challenges for Developing Countries: 
An Economic Perspective, 2001 U. ILL. L. REV. 457,457 (2001). 
133 Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 
1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 
in LEGAL INSTRUMENTS-RESULTS OF THE URUGUAY ROUND vol. 31, 33 I.L.M. 81, at 
art. 7 (1994) [hereinafter TRIPS Agreement). 
134 Peter Jiang, Fighting the AIDS Epidemic: China's Options Under the WTO 
Trips Agreement, 13 ALB. L.J. SCI. & TECH. 223, 235 (2002). 
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infrastructure, thels are predominantly consumers of 
foreign technology. 1 5 For them, enforcing foreign patents 
dramatically increases the cost of imported drugs and 
inhibits local industry.136 Moreover, lacking patents of their 
own, least developed countries receive few reciprocal 
benefits by supporting strong international patent 
t t · 137 pro ec IOn. 
The tension between developed and developing world 
perspectives is reflected in the Universal Declaration of 
Human Rights (UDHR).138 On the one hand, the UDHR 
guarantees the right to property139 and the protection of 
material interests resulting from scientific discovery.14o On 
the other hand, it guarantees the right to health,141 
education,142 and to share in scientific advancement and its 
benefits.143 Developed countries seek the right to protection 
of their proprietary interests resulting from scientific 
discovery, while least developed countries seek the right to 
share in scientific discoveries and to the health of the 
I t · 144 popu a Ion. 
WTO rules do provide limited methods of circumventing 
intellectual property rules where necessary to protect the 
public's health. Article 31 of TRIPS provides for a 
135 James Otieno-Odek, Public Domain in Patentability After the Uruguay Round: 
A Developing Country's Perspective with Specific Reference to Kenya, 4 TuL. J. INT'L 
& COMPo L. 15, 24 (1995); Nermien Al-Ali, The Egyptian Pharmaceutical Industry 
After TRIPS-A Practitioner's View, 26 FORDHAM INT'L L.J. 274, 277 (2003). 
136 Al-Ali, supra note 135, at 277. 
137 Otieno-Odek, supra note 135, at 24; Christopher J. Kay, Harmonization and 
Intellectual Property Human Rights in Least Developed Countries, (Dec. 21, 2001) 
(unpublished paper, Georgetown University Law Center, Health and Human Rights 
Seminar, on file with author). 
138 See Universal Declaration of Human Rights, G.A. Res. 217A (III), U.N. Doc. 
Al810, at 71 (1948), available at http://www.un.org/Overview/rights.html (last visited 
Mar. 15,2003). 
139 Id. art. 17. 
140 [d. art. 27(2). 
141 Id. art. 25. 
142 Id. art. 26. 
143 [d. art. 27(1). 
144 Murashige, supra note 131, at 605. 
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compulsory license, which authorizes a government to 
transfer patent rights to itself or a third party without the 
patent-holder's consent under specified circumstances. 145 
One of the designated circumstances is when the public 
interest necessitates abrogation of ~atent rights, for 
example in a national health emergency. 46 
Although compulsory licenses are enshrined in TRIPS, 
pharmaceutical companies, supported by Northern 
governments, have strongly resisted claims of a national 
health emergency, preferring to maintain their patents. 
For example, Thailand, under intense pressure from the 
United States, amended its law to provide patent protection 
for drugs and to limit compulsory licensing and importation 
of patented drugs. 147 This occurred against a backdrop of an 
epidemic in which one million people are infected with HIV 
and where AIDS is the leading cause of death. 148 
Many of the least developed countries have a powerful 
argument that the AIDS pandemic has caused a national 
health emergency. In Kenya, nearly 700 people die from 
HIV disease daily, but antiretroviral treatment is out of 
reach for the majority of the population. 149 The U.S. Census 
Bureau estimates that the HIV/AIDS epidemic has reduced 
life expectancy in South Africa by fifteen yearsl50 and in 
Zimbabwe by thirty-two years. 151 Compare these 
145 TRIPS Agreement, supra note 133, art. 3l. 
146 Universal Declaration of Human Rights, supra note 138, art. 31(b). 
147 Rosemary Sweeney, The U.S. Push for Worldwide Patent Protection for Drugs 
Meets the AIDS Crisis in Thailand: A Devastating Collision, 9 PAC. RIM L. & POL'y J. 
445·46, 449 (2000). 
148 See STANECKI, supra note 10, at 3·4. 
149 Doris K. Macharia et aI., Antiretroviral Therapy in the Private Sector of 
Nairobe, Kenya: A Review of the Experience of Five Physicians, 17 AIDS 938, 938 
(2003). 
150 U.S. CENSUS BUREAU, HIV/AIDS SURVEILLANCE: TRENDS AND PATTERNS OF 
HIV INFECTION IN SELECTED DEVELOPING COUNTRIES (2000), available at 
httE://www.census.gov/ipc/hiv/safrica.pdf(last visited Apr. 12, 2003). 
1 1 U.S. CENSUS BUREAU, HIV/AIDS SURVEILLANCE: TRENDS AND PATTERNS OF 
HIV INFECTION IN SELECTED DEVELOPING COUNTRIES, 2000, available at 
http://www.census.gov/ipc/hiv/Zimbabwe.pdf(lastvisitedApr. 15,2003). 
HeinOnline -- 17 Emory Int’l L. Rev. 35 2003
2003] THE GLOBAL REACH OF HIV/AIDS 35 
justifications for compulsory licenses with those made by 
political leaders in the United States in response to the 
intentional release of anthrax in 2001 even though there 
were only a half dozen deaths from anthrax.152 Politicians 
suggested that the United States exercise its compulsory 
licensing privilege under the TRIPS agreement to permit 
cheap production of the antibiotic Cipro, without the 
consent of Bayer Pharmaceuticals. 153 
There are creative ways to relax rigid trade rules to allow 
less developed countries to obtain essential medicines at a 
more affordable cost. Through the innovative thinking of 
political leaders in developed and less developed countries, 
the criteria for the issuance of compulsory licenses under 
Article 31 of TRIPS could be clarified.154 The international 
trade system should recognize the devastating public health 
effects of HI VIA IDS in resource-poor countries. 
B. Poor Countries Making AIDS Treatments Available and 
Affordable 
Several countries have already asserted the right to 
produce or purchase generic drugs at significantly reduced 
cost.155 For example, low cost drugs are manufactured by 
Brazil, Thailand, and India.156 Generic medications can 
152 James M. Hughes & Julie L. Gerberding, Anthrax Bioterrorism: Lessons 
Learned and Future Directions, 8 EMERGING INFECTIOUS DISEASES 1013, 1013 
(2002). 
153 Ed Silverman & David Schwab, U.S. Will Respect Cipro Patent-Feds Opt Not 
to Allow Copies of Antibiotic, THE STAR-LEDGER (Newark, N.J'), Oct. 18, 2001, at 25 
(noting that one U.S. Senator asked the White House to invoke a law that permits 
federal officials to both disregard a federal patent and issue a compulsory license to 
other companies). 
154 See, e.g., Thomas A. Haag, TRIPS Since Doha, How Far Will the WHO Go 
Toward Modifying the Terms for Compulsory Licensing?, 84 J. PAT. & TRADEMARK 
OFF. SOC'Y 945 passim (2002) (discussing the possibilities to modify Article 31 of 
TRIPS). 
155 Clare Kapp, WHO Faces Funding Squeeze as Richer Countries Make a Stand, 
357 LANCET 1683, 1683 (2001). 
156 Boseley, supra note 95. 
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reduce the cost of a daily treatment of AZT, 3TC and 
nevi rapine from $3.20 to $1.55.157 After conducting research 
trials to determine the safety and efficacy of imported 
generic HIV/AIDS drugs/58 countries such as Nigeria have 
decided to begin importing them. 159 The actions of these 
states are driven by a need and desire to provide for their 
·t· 160 Cllzens. 
These actions, however, have been contested. The United 
States has attempted to use the WTO to force conformity 
with international patent law. It began, although later 
dropped, proceedings against Brazil for production of 
generic HIV/AIDS drugs. 161 In 2001, a conglomerate of 
forty-one major drug companies sued the South African 
government in the South African courts to block the 1997 
Medicines Act, on the grounds that it was a breach of 
international patent protection. 162 Following intense 
international pressure, culminating in a petition to "Drop 
the Case" signed by 260,000 people and 140 organizations 
in 130 countries, the companies withdrew the lawsuit. 163 
157 S. Africa.AIDS.Drugs: AIDS Activists Defy Law by Bring Anti·AIDS Drugs 
into S. Africa, Jan. 29, 2002, (noting that generic versions of antiretroviral drugs 
would reduce the daily cost of treatment by one half: $3.20 to $1.55), at 
http://www.aegis.com/news/afpl2002lAF020150.html (last visited Mar. 31, 2003). 
158 Nigeria Buying Generic Drugs for an AIDS Treatment Trial, N.Y. TIMES, Nov. 
30, 2001, at A12. 
159 Chris McGreal, Defiant Nigeria to Import Cheap Copies of HN Drugs, THE 
GUARDIAN, Dec. 11, 2001, at 2, available at www.guardian.co.uklaids/story/ 
0,7369,616827,00.html (last visited Mar. 15,2003). 
160 GLOBAL MANIFESTO, DURBAN SOUTH AFRICA (2000) (proclaiming "We are 
united with a single purpose, to ensure that everyone with HIV and AIDS has access 
to fundamental rights of healthcare and access to life·sustaining medicines. AIDS 
has become a catastrophe that threatens the very future of this planet."), available 
at http://www.actupny.org/reportsldurban-access.html (last visited Mar. 15,2003). 
161 US Drops Brazil AIDS Drugs Case, BBC NEWS, June 25, 2001, available at 
http://news.bbc.co. ukl2/hilenglish/business/newsid_1407000/1407 4 72.stm (last 
visited Mar. 27, 2003). 
162 See, e.g., Carla Power et aI., Paying for AIDS, NEWSWEEK INT'L, Mar. 19, 
2001, at 16-17. 
163 Press Release, Medecins Sans Frontieres, Drug Companies in South Africa 
Capitulate Under Barrage of Public Pressure (Apr. 19, 2001), available at 
http://www.lists.doctorswithoutborders.org/pr/2001l04·19-200l.shtml (last visited 
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Surprisingly, despite the consistently negative response 
of the United States and multinational companies, 
international law experts have supported the right of least 
developed countries to circumvent patent rights to 
safeguard the public's health.164 The decision to drop the 
litigation in South Africa was also greeted by positive 
responses from bodies as diverse as Doctors without 
Borders/65 UNAIDS,166 and the WTO itself, whose Director-
General, Mike Moore, felt that the settlement proved that 
"WTO Agreements, such as TRIPS, contain the necessary 
flexibility to meet the health needs of developing 
t · ,,167 coun nes. 
The HIV/AIDS pandemic has turned the patent question 
into an explosive issue, forcing the WTO to resolve the 
problem. In November 2001, in Doha, Qatar, the 
Ministerial Conference of WTO declared that TRIPS should 
be interpreted to support public health and allow for 
patents to be overridden if required to respond to 
emergencies such as the AIDS epidemic.168 While a major 
achievement, the declaration ignored one significant 
problem. Countries with little or no manufacturing 
capability must import drugs. The Doha rules allowed 
them to break patents to import, but did not authorize 
countries to override patents for the purposes of export to 
countries in need.169 In December 2002 in Geneva, although 
Mar. 15, 2003). 
164 Michael Halewood, Regulating Patent Holders: Local Working Requirements 
and Compulsory Licenses at International Law, 35 OSGOODE HALL L.J. 243 passim 
(1997). 
165 Medecins Sans Frontieres, supra note 163. 
166 Press Release, UNAIDS, UNAIDS Welcomes Outcome of South Mrican Court 
Case (Apr. 19,2001), available at http://www.unaids.org/whatsnew/press/eng/pressa 
rcOl/SAfrica_190401.htm (last visited Mar. 15, 2003). 
167 Mike Moore, Moore Welcomes News of Settlement of South Africa Drug 
Lawsuit, (Apr. 19, 2001), available at http://www.wto.org/englishlnews_e/spmm_e/ 
spmm58_e.htm (last visited Mar. 15, 2003). 
168 Declaration on the TRIPS Agreement and Public Health, Nov. 14, 2001, 
Ministerial Conference, 4th Session, para. 4, WTIMIN(01)IDEC/2 (2001) [hereinafter 
Declaration on the TRIPS AgreementJ. 
169 Haag, supra note 154, at 947, 951-52; Declaration on the TRIPS Agreement, 
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143 of the WTO's 144 members agreed on a solution, the 
lone holdout, the United States, obstructed the 
agreement.170 American negotiators lobbied to limit covered 
medicines to those for HIV/AIDS, malaria, tuberculosis, and 
a few diseases that affect primarily Africa. l7l Other 
countries wanted a more flexible approach on access to 
medicines that allows nations to protect public health as 
they see fit.172 As a result, no agreement was reached by the 
time that the talks ended. After the debacle in Geneva, the 
Bush administration pledged not to bring trade pressure 
against countries that export cheap drugs for HIV/AIDS 
and other resource-poor country epidemic diseases.173 
C. Non-Price Barriers to Treatment Access: Infrastructure and 
National Priorities 
Much of the discourse on barriers to access to HIV 
treatments has concentrated on the issue of price. 
However, price is not the only barrier, and it is probably not 
even the most difficult one to overcome. The problems of 
fair and efficient methods of dissemination to people in 
need remain. 174 Allocation and distribution of drugs within 
crowded cities, among homeless people, and in remote 
villages requires organized transportation and 
communication systems. The health care system may not 
be capable of accurately diagnosing HIV, monitoring viral 
load, and checking for adverse reactions. Patients must 
supra note 168, para. 4. 
170 Jeffrey Sparshott, U.S. Refusal Thwarts WTO Drug-Patent Talks, WASH. 
POST, Dec. 25, 2002, at CW. 
171 Haag, supra note 154, at 955. 
172 Id. at 947, 956-59. 
173 Michael M. Phillips, U.S. Eases Drug-Patent Rules, WALL ST. J., Dec. 23, 2002, 
atA4. 
174 See BUREAU OF OCEANS & INT'L ENVTL. & SCI. AFF., U.S. DEP'T OF ST., 1999 
U.S. INTERNATIONAL RESPONSE TO HIV/AIDS (1999) (noting a "sophisticated health 
provider and laboratory infrastructures" are also necessary to treat persons with 
HIV in developing countries successfully), at http://www.state.gov/www/global/oesl 
healthlI999_hivaids_rptlagency_strats.html (last visited Mar. 15,2003). 
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also be educated correctly about the strict regimen of taking 
medication. 
Taken together, these problems mean that, even if 
distribution can be achieved, the drug may not be 
prescribed or taken appropriately. Incorrect or intermittent 
use of antiretroviral medications would create serious 
health risks for individual patients and pose a wider risk to 
the population; public health agencies are concerned that 
the virus could become resistant to existing medicines, 
rendering them less effective. The problems of resistance to 
antiretroviral medication already exist.175 They would be 
exacerbated by large scale distribution to patients who do 
not have the health care and support systems needed to 
ensure appropriate use. These concerns are legitimate and 
often on the minds of Northern states and aid donors. 
However, care must be taken as they touch on sensitive 
issues. The public health community must reexamine the 
issue of HIV / AIDS medications in poor countries in the 
setting of rising mortality, falling drug prices, and 
innovative methods of drug delivery. Reacting to a 
comment by u.S. Agency for International Development 
Director Andrew N atsios, who indicated that Mricans could 
not handle antiretroviral drugs because they had no concept 
of time, the Zimbabwe Health Minister, Timothy Stamps, 
said: "Though we do not have clocks and roads in Mrica we 
do know the time and time is ticking away inexorably for 
some of our states."176 In response to legitimate demands, 
researchers are developing cheap, simple, and effective 
alternative treatments and monitoring technologies to 
Improve the medical management of patients on 
175 Dirk Albrecht et al., Reappearance of HN Multidrug-Resistance in Plasma 
and Circulating Lymphocytes after Reintroduction of Antiretroviral Therapy, 24 J. 
CLINICAL VIROLOGY 93 passim (2002). 
176 Brian Conway et al., Development of Drug Resistance in Patients Receiving 
Combinations of Zidovudine, Didanosine, and Nevirapine, 15 AIDS 1269 passim 
(2001). 
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antiretroviral therapy.177 For instance, in Haiti, researchers 
successfully used a directly observed therapy (DOT) 
program to monitor HAART (DOT-HAART) in HIV 
patients.178 
Making expensive HIV medications widely available 
would also raise questions of equity and cost-effectiveness. 
No one doubts that the appropriate use of these drugs 
would provide substantial benefits to patients and their 
communities. But some may ask why persons living with 
HIV/AIDS should receive special consideration. Many 
endemic diseases in developing countries could be 
prevented or treated with vaccines or pharmaceuticals that 
are not accessible to the population, including simple 
interventions such as penicillin and oral rehydration. For 
example, isoniazid and co-trimoxazloe prophylaxis against 
tuberculosisl79 and pneumonia respectively are highly 
effective but rarely available to poor people in less 
developed countries. 180 Similarly, almost eighteen million 
people, mostly in Mrica and Central or South America, are 
infected with onchocerciasis (river blindness) which is 
curable by administering a single oral dose of I vermectin 
(trade name: Mectizan) per year.181 Interventions for these 
and many other diseases may be more cost effective, and 
entail less risk than for the most expensive HIV therapies. 
Similarly, if the extensive resources needed to purchase, 
177 Joan Stephenson, Cheaper HIV Drugs for Poor Nations Bring a New 
Challenge: Monitoring Treatment, 288 JAMA 151,151 (2002); Paul J. Weidle et aI., 
HIV I AIDS Treatment and HIV Vaccines for Africa, 359 LANCET 2261,2261 (2002). 
178 Farmer, supra note 105, at 1147. 
179 Rajesh Gupta et aI., Responding to Market Failures in Tuberculosis Control, 
293 SCI. 1049, 1049 (2001). 
ISO Karen Zwi et aI., Cheaper Antiretrovirals to Treat AIDS in South Africa: They 
Are At Their Most Cost Effective in Preventing Mother to Child Transmission, 320 
BRIT. MED. J. 1551, 1551 (2000). 
181 THE CARTER CENTER, River Blindness Program (stating that in response to 
the widespread onchocerciasis infections, the manufacturer of Mectizan has 
"donated the drug treatments to the world for as long as there is a need"), available 
at 
http://www.cartercenter.org/healthprogramsishowdoc.asp?programID=2&submenu= 
heaIthprograms (last visited Mar. 26, 2003). 
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distribute, and monitor HIV drugs were used for other 
pressing needs such as food, sanitation and primary health 
care, lives might be saved at a lower cost. For example, the 
percent of children in sub-Saharan countries who are 
malnourished has steadily increased since 1970/82 thirty-
eight percent of inhabitants do not have access to safe 
water/83 and the lifetime risk of maternal death due to 
inadequate family planning and health care can be as high 
• • 184 
as one In mne. 
These difficult problems of resource allocation are 
endemic in the developing world and in the response to 
HIV/AIDS specifically. They have been a recurring theme 
of this Article and raise several important questions. What 
are the best uses for scarce public health and health care 
resources? Should significant funding be devoted for, say, 
high cost antiretroviral treatment or for more basic health 
services, including antenatal care, primary health care, and 
tuberculosis and Sexually Transmitted Diseases (STD) 
treatment? Should intellectual property be protected to 
spur investment and innovation or should patents be 
relaxed to ensure access to life-saving medications in the 
least developed countries? 
There are no easy answers to these and other dilemmas, 
but one thing is clear. The most developed countries of the 
North and West have failed utterly to see the critical need 
for sharing resources with the South and East. These 
highly industrialized countries may have articulated the 
humanitarian arguments that lie at the heart of 
international aid, but they have provided only a small 
fraction of the resources necessary to implement them. 
182 Per Pinstrup-Andersen, Nutrition and Development, INT'L FOOD POL'y RES. 
INST. 1 (Nov. 2000). 
183 UNITED NATIONS CHILDREN'S FUND, GLOBAL WATER SUPPLY AND SANITATION 
SECTOR REPORT 41 (2000), available at http://www.unicef.org/programme/wes/ 
pubs/global/global.htm (last visited Mar. 24, 2003). 
184 Carolyn Lay, Family Planning Access is Seen as Key Determinant in Maternal 
Well Being, 22 POPLINE 3 (2000), available at http://population.newc.com/teampu 
blishiuploadslMay-June_2000_Issue.pdf(last visited Apr. 12,2003). 
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This is not only a tragedy for resource-poor countries, but 
will affect the health, economy, and security of people 
everywhere. 
III. THE ETHICS OF HUMAN SUBJECT RESEARCH 
Global success in combating HIV/AIDS must be 
measured by its impact on our children and young 
people. Are they getting the information they need 
to protect themselves from HIV? Are girls being 
empowered to take charge of their sexuality? Are 
infants safe from the disease, and are children 
orphaned by AIDS being raised in loving, supportive 
environments? These are the hard questions we 
need to be asking. These are the yardsticks for 
measuring our leaders. We cannot let another 
generation be devastated by AIDS. 
Carol Bellamy, Executive Director, UNICEF 
(2002). 
A. Reduction of Perinatal Transmission in Resource-Poor 
Countries 
Vertical transmission of HIV from mother to child occurs 
intrauterine (i.e., inside the uterus), intrapartum (i.e., 
during labor and delivery), and postpartum during breast-
feeding. ls5 UNAIDS and WHO estimate that of the over two 
million HIV-infected women giving birth each year, 
approximately 600,000, or thirty percent, transmit the 
infection to their children. ls6 With over ninety percent of 
185 Beth R. Santmyire, Vertical Transmission of HN from Mother to Child in Sub-
Saharan Africa: Modes of Transmission and Methods for Prevention, 56 
OBSTETRICAL & GYNECOLOGICAL SURV. 306, 306 (2001). 
186 M. Berer, Reducing Perinatal HN Transmission in Developing Countries 
Through Antenatal and Delivery Care, and Breastfeeding: Supporting Infant 
Survival by Supporting Women's Survival, 77 BULL. WORLD HEALTH ORG. 871, 871 
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the world's HIV-infected children living in sub-Saharan 
Mrica, the rate of HIV infection among women attending 
antenatal clinics in this region ranges from ten to fifty 
percent. IS7 Studies suggest that in Mrica, approximately 
sixty-five thru seventy percent of HIV transmission occurs 
intrapartum, nineteen thru twenty-three percent 
intrauterine, and eleven through twelve percent 
postpartum. In the absence of intervention, vertical 
transmission is estimated to be fourteen through twenty-
five percent in developed countries and twenty-one through 
forty-three percent in less developed countries;188 the 
difference in rates of transmission are due mostly to breast 
feeding in less developed countries. 
The administration of antiretroviral agents to mother and 
child around the time of birth may be the most effective 
means of an intervention to reduce vertical transmission 
although substitution of formula feeding for breast feeding, 
and caesarean section are viable alternatives. Numerous 
international observational studies have reported 
significant reductions in vertical transmission with 
treatment. IS9 . In 1994, the AIDS Clinical Trial Group Study 
076 ("ACTG 076") showed a two-thirds reduction in 
transmission from HIV-infected women who received a 
complex regimen of zidovudine, an antiretroviral agent, for 
themselves and their infants.19o Impressive decreases in 
vertical HIV transmission have been achieved in North 
(1999); Chewe Luo, Strategies for Prevention of Mother-to-Child Transmission of 
HN, 8 REPROD. HEALTH MATTERS 144, 144 (2000). 
187 UNAIDS, AIDS in Africa, at http://www.unaids.org/publications/documents/ 
epidemioIogy/determinants/saepap98.htmI (last visited Mar. 24, 2003). 
188 Francois Dabis et al., Rates of Mother-to-Child Transmission of HN-1 in 
Africa, America and Europe: Results from 13 Perinatal Studies, 8 (5) J. ACQUIRED 
IMMUNODEFICIENCY SYNDROME & HUMAN RETROVIROLOGY 506, 508 (1995). 
189 Kevin M. De Cock et al., Prevention of Mother-to-Child HN Transmission in 
Resource-Poor Countries: Translating Research into Policy and Practice, 283 JAMA 
1175, 1175 (2000). 
190 Edward M. Connor et al., Reduction of Maternal-Infant Transmission of 
Human Immunodeficiency Virus Type 1 with Zidovudine Treatment, 331 NEW ENG. 
J. MED. 1173, 1173 (1994). 
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America and Europe based on these clinical trials. 191 While 
formula feeding can reduce the risk of HIV transmission, it 
creates other risks because breast-feeding has nutritional, 
immunological, and birth spacing benefits that deserve 
preservation if possible. 192 In addition, formula feeding 
requires access to nutritionally sound formulas and potable 
water, which may be scarce in some regions. Caesarean 
section also reduces vertical transmission, although its cost 
effectiveness is not established and it is not feasible m 
areas with few resources. 193 
The success in reducing vertical transmission in 
industrialized countries through antiretroviral therapy 
stands in stark contrast to the continuing perinatal HIV 
epidemic in less developed countries. 194 In low-resource 
settings, where infants of infected mothers are continuously 
exposed to HIV, the cost of the regimen used in ACTG 076 
is too expensive and complex. The estimated cost of the 
regimen is $200 (with discounts in pricing to less developed 
countries), which makes the treatment unavailable to most 
people in sub-Saharan Mrica where the annual health 
expenditure per person is between $2 and $40.195 Additional 
barriers include the difficulty in compliance with a regimen 
entailing administration of a drug four or five times daily 
for weeks, limited infrastructure for distributing drugs and 
monitoring compliance, and inadequate maternal-child 
health care services. 
191 Mary Lou Lindegren et al., Trends in Perinatal Transmission of HN / AIDS in 
the United States, 282 JAMA 531 passim (1999). 
192 Angus Nicoll et al., Infant Feeding Policy and Practice in the Presence of HN-l 
Infection, 9 AIDS 107, 107 (1995). 
193 Elective Caesarean-Section Versus Vaginal Delivery in Prevention of Vertical 
HN-l Transmission: A Randomised Clinical Trial, 353 LANCET 1035,1035 (1999). 
194 Lynne M. Mofesnson & James A. McIntyre, Advances and Research Directions 
in the Prevention of Mother-to-Child HN-l Transmission, 355 LANCET 2237, 2237 
(2000). 
195 Elliot Marseille et al., Cost Effectiveness of Single·Dose Nevirapine Regimen 
for Mothers and Babies to Decrease Vertical HN·l Transmission in Sub·Saharan 
Africa, 354 LANCET 803, 803 (1999). 
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Research in sub-Saharan Mrica and Southeast Asia has 
demonstrated that less expensive short-course 
antiretroviral regimens diminish perinatal transmission by 
one-third to one-half.196 A trial in Uganda of a single oral 
dose of nevirapine, an antiretroviral dru~, given to the 
mother and newborn had similar benefits.19 These results 
applied to women who did/9a and did not/99 breast-feed, 
although the formula-fed groups had even greater 
reductions in transmission. Economic analyses have 
suggested that short-course therapies can achieve 
significant health and financial benefits considering the 
cost of the therapy.2oo As a result, WHO and UNAIDS 
recommend short-course perinatal antiretroviral therapy 
and advise HIV-infected women not to breast-feed their 
infants where this can be accomplished safely.20I 
Despite the clinical research, economic analysis, and 
public health guidance, few developing countries (with the 
exception, for example, of Botswana, Thailand, and Brazil) 
have national policies for integration of preventive 
196 Fran<;ois Dabis et aI., 6-Month Efficacy, Tolerance, and Acceptability of a Short 
Regimen of Oral Zidovudine to Reduce Vertical Transmission of HN in Breastfed 
Children in Cote d'[voire and Burkina Faso: A Double-Blind Placebo-Controlled 
Multicentre Trial, 353 LANCET 786, 786 (1999); Stefan Z. Wiktor et aI., Short-Course 
Oral Zidovudine for Prevention of Mother-to-Child Transmission of HN-1 in 
Abidjan, Cote d'Ivoire: A Randomised Trial, 353 LANCET 781, 781 (1999); Nathan 
Shaffer et aI., Short-Course Zidovudine for Perinatal Transmission in Bangkok, 
Thailand: A Randomised Controlled Trial, 353 LANCET 773, 773 (1999). 
197 Laura A. Guay et aI., Intrapartum and Neonatal Single-Dose Nevirapine 
Compared with Zidovudine for Prevention of Mother-to-Child Transmission of HN-1 
in Kampala, Uganda: HNNET 012 Randomised Trial, 354 LANCET 795,795 (1999). 
198 Id. 
199 CENTERS FOR DISEASE CONTROL & PREVENTION, Administration of 
Zidovudine During Late Pregnancy and Delivery to Prevent Perinatal HN 
Transmission-Thailand 1996-1998, 47 MORBIDITY & MORTALITY WKLY. REP. 151, 
151 (1998). 
200 Soderlund, supra note 81 passim. 
201 UNICEF, UNAIDS, & WORLD HEALTH ORG., HIV AND INFANT FEEDING: 
GUIDELINES FOR DECISION-MAKERS (1998), available at http://www.unaids.org/ 
publicationsidocumentslmtctJinfantpolicy.html (last visited Mar. 25, 2003); Berer, 
supra note 186, at 871-75. 
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antiretroviral therapy in antenatal clinics.202 As discussed 
below, those resisting these kinds of interventions object on 
grounds of economics203 and ethics. 204 Neither the economic 
nor the ethical arguments are convincing. In fact, citizens 
and advocacy groups have powerfully influenced 
government policy, as exemplified by the successful suit by 
the Treatment Action Campaign (TAC) in South Mrica as 
previously discussed.205 
Economic objections understandably rest on the still 
relatively high cost of short course therapies when 
compared to meager health budgets, and on the need to 
have a reasonably well-functioning health care system. 
There are also arguments based on distributive justice, for 
example, why HIV should hold a special status. But 
prevention of perinatal transmission, which can be achieved 
sometimes with a single dose, will save countless lives of 
young people with productive futures. The economic 
benefits of preventing perinatal transmission cannot be 
compared with treatment once the disease has taken hold, 
which requires far more expensive, complex, and arduous 
treatment regimes over the course of a lifetime. 
The ethical objections to short-course therapy rest 
primarily on the need for voluntary counseling and testing 
before administration of antiretroviral drugs. Some believe 
that poor, uneducated women cannot give fully informed 
and voluntary consent to testing and treatment. However, 
informing women III ways that are culturally and 
202 Luo, supra note 186, at 144. 
203 David Wilkinson et ai., Short Course Antiretroviral Regimens to Reduce 
Maternal Transmission of HN: May be Effective but Shouldn't be Allowed to 
Strangle Research that Might Help Africans, 318 BRIT. MED. J. 479 passim (1999). 
204 Catherine Hankins, Preventing Mother-to-Child Transmission of HN in 
Developing Countries: Recent Developments and Ethical Implications, 8 REPROD. 
HEALTH MATTERS 87 passim (2000). 
205 Chris McGreal, Court Orders Mbeki to Provide AIDS Drug, THE GUARDIAN, 
Dec. 15, 2001, at http://www.guardian.co.uk/aids/story/0,7369,619153,00. html (last 
visited Mar. 20, 2003); South Africa to Provide AIDS Drug, BBC NEWS, Apr. 4, 2002, 
at AI. 
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linguistically appropriate can ensure voluntary and 
informed consent.206 Another alternative is to offer 
routinely a single dose of nevirapine orally to the mother 
and to the infant without the need for an HIV test. Given 
the devastation of the perinatal HIV epidemic and the 
availability of uncomplicated, inexpensive interventions, it 
ought to be possible to relieve the suffering and loss of life 
in developing countries. 
Women and children, wherever they live, deserve a 
comprehensive package of care in pregnancy, during 
delivery, and after birth. UNAIDS, UNICEF, and WHO 
recommend: early access to perinatal care, voluntary and 
confidential counseling and HIV testing for women and 
their partners, antiretroviral preventative therapy, care 
during labor and delivery, and counseling on alternative 
methods of infant feeding including support for those who 
choose breast-feeding replacements. 207 Additionally, women 
deserve access to methods of family planning, children 
deserve post-natal care, and families deserve nutritional 
and social support. 208 
B. The Controversy Over Research Ethics in International 
Collaborative Research 
It is clear that short-course antiretroviral therapy can 
have enormous benefits for less developed countries. But 
this utilitarian argument has been challenged as an 
insufficient justification for conducting research trials in 
Mrica, Asia, and the Caribbean to determine the efficacy of 
a low-dose regimen of zidovudine (AZT) in pregnant 
206 Carel B. Ijsselmuiden & Ruth Faden, Research and Informed Consent in 
Africa-Another Look, 326 NEW ENG. J. MED. 830, 833 (1992). 
207 Berer, supra note 186, at 871. 
208 Luo, supra note 186, at 144; Rachel Baggaley & Eric van Praag, Antiretroviral 
Interventions to Reduce Mother-to-Child Transmission of Human Immunodeficiency 
Virus: Challenges for Health Systems, Communities and Society, 78 BULL. WORLD 
HEALTH ORG. 1036, 1036 (2000). 
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women.
209 Fifteen placebo-controlled trials (PCTs?lO were 
conducted in the mid-to-late 1990s in developing 
countries. 211 A trial conducted in Thailand was an 
equivalency trial in which a regimen that has already been 
proven effective (the ACTG 076 regimen) was compared 
with a second regimen (low dose antiretrovirals) to 
determine if it is as effective, but less toxic or expensive.212 
Most of the studies were funded by the National Institutes 
of Health (NIH) and the Centers for Disease Control and 
Prevention (CDC), while the others were funded by 
European countries, South Mrica, and UNAIDS.213 
There is no doubt that if these PCTs had been conducted 
in the United States they would have been regarded as 
unethical. No trial would be ethically approved in a 
developed country if it denied access to an intervention 
thought to hold promise of being at least as effective as, if 
not more effective than, the prevailing standard of care. 
The question posed is whether it is ethical to withhold a 
treatment in a poor country, when the treatment is used as 
the standard of care in developed countries but is not 
attainable in the country in which the research is taking 
place.214 The issue is not whether it is ethical for First 
World researchers to investigate a therapy that would be 
out-of-reach or unimportant in the country in which the 
209 Zulfiqar A. Bhutta, Ethics in International Health Research: A Perspective 
from the Developing World, 80 BULL. WORLD HEALTH ORG. 114, 115 (2002), 
available at http://www.who.int/bulietinlpdfl2002/bul-2-E-2002l80(2)114-120.pdf 
(last visited Apr. 10,2003). 
210 In a placebo controlled trial, one group of persons is given the experimental 
treatment, and one group (the control group) is given a placebo, such as a sugar pill. 
The incidence of transmission in the two groups is compared to determine whether 
the experimental treatment had any effect. 
211 Bhutta, supra note 209, at 115; Ronald Bayer, Ethical Challenges of HN 
Vaccine Trials in Less Developed Nations: Conflict and Consensus in the 
International Arena, 14 AIDS 1051, 1054 (2000). 
212 Bayer, supra note 211, at 1054. 
213 Ronald Bayer, The Debate Over Maternal-Fetal HN Transmission Prevention 
Trials in Africa, Asia, and the Caribbean: Racist Exploitation or Exploitation of 
Racism?, 88 AM. J. PuB. HEALTH 567,567 (1998). 
214 Id. 
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research takes place (e.g., testing high technology 
interventions for cancer in the least developed countries). 
International collaborative research that is of little benefit 
to the host country arguably is unethical, but the short-
course protocols were deliberately designed to find 
affordable treatments in developing countries.215 
The short-course studies provoked a storm of 
controversy. 216 Critics argued that placebo controls were 
never justified when an effective treatment exists; subjects 
in the control group must receive the "best known 
treatment," meaning the highest standard that would be 
available in developed countries.217 Critics argued that high 
levels of care for research subjects were mandated by the 
Helsinki Declaration which was revised in 2000: "A new 
method should be tested against... the best current 
prophylactic, diagnostic, and therapeutic methods. This 
does not exclude the use of placebo, or no treatment, in 
studies where no proven prophylactic, diagnostic or 
therapeutic method exists.,,218 Critics also cited the Council 
of International Organizations of Medical Societies' 
(CIOMS) Guidelines on Biomedical Research, which state 
that ethical and scientific review should be conducted 
according to the standards of the sponsoring agency and 
should be "no less exacting" than if conducted in the 
sponsoring country.219 In draft revisions to the guidelines, 
CIOMS states that the Helsinki standard should be adopted 
unless there are sound reasons to use a control, such as 
215 Harold Varmus & David Satcher, Ethical Complexities of Conducting Research 
in Developing Countries, 337 NEW ENG. J. MED. 1003, 1004 (1997). 
216 Peter Lurie & Sidney M. Wolf, Unethical Trials of Interventions to Reduce 
Perinatal Transmission of the Human Immunodeficiency Virus in Developing 
Countries, 337 NEW ENG. J. MED. 853, 853-54 (1997). 
217 Marcia Angell, The Ethics of Clinical Research in the Third World, 337 NEW 
ENG. J. MED. 847, 848 (1997). 
218 WORLD MED. AsS'N DECLARATION OF HELSINKI, ETHICAL PRINCIPLES FOR 
MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (2000), available at 
http://www.wma.netJe/policY/17-c_e.html (last visited Mar. 25, 2003). 
219 Council for Int'l Org. of Medical Sciences, International Guidelines for Ethical 
Review of Epidemiological Studies, 19 L. MED. & HEALTH CARE 191, 191 (1991). 
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when withholding the best current treatment would result 
in no serious adverse effect and a comparative study of two 
treatments would yield no reliable scientific results. 220 
Other scholars have elaborated on the ethical conditions 
that would justify use of PCTs in cases where there is a 
proven treatment.221 
Marcia Angell, then editor of the New England Journal of 
Medicine, harshly compared the short-course trials to the 
infamous study in Tuskegee, Alabama where African 
American men with syphilis were simply observed and left 
untreated: 
Women in the Third World would not receive 
antiretroviral treatment anyway, so the investigators 
are simply observing what would happen to the 
subjects' infants if there were no study. And a 
placebo-controlled study is the fastest, most efficient 
way to obtain unambiguous information that will be of 
greatest value in the Third World.222 
Angell criticized this logic: "All the rationalizations boil 
down to asserting that the end justifies the means-which 
it no more does in Africa than it did in Alabama.,,223 
Harold Varmus and David Satcher, then heads of NIH 
and CDC respectively, responded vigorously: 
[Critics] allude inappropriately to the infamous 
Tuskegee study, which did not test an intervention. 
220 Patricia Huston & Robert Peterson, Withholding Proven Treatment in Clinical 
Research, 345 NEW ENG. J. MED. 912, 912 (2001). 
221 Ezekiel J. Emanuel & Franklin G. Miller, The Ethics of Placebo-Controlled 
Trials-A Middle Ground, 345 NEW ENG. J. MED. 915, 915 (2001); Benjamin 
Freedman et aI., Placebo Orthodoxy in Clinical Research II: Ethical, Legal, and 
Regulatory Myths, 24 J. LAw, MED., & ETHICS 252, 252 (1996); Benjamin Freedman 
et al., Placebo Orthodoxy in Clinical Research I: Empirical and Methodological 
Myths, 24 J. LAW MED. & ETHICS 243,243 (1996). 
222 Angell, supra note 217, at 848. 
223 Marcia Angell, Tuskegee Revisited, WALL ST. J., Oct. 28, 1997, at A22. 
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The Tuskegee study ultimately deprived people of a 
known, effective, affordable intervention. To claim 
that countries seeking help in stemming the tide of 
maternal-infant HIV transmission by seeking usable 
interventions have followed that path trivializes the 
suffering of the men in the Tuskegee study and shows 
a serious lack of understanding oftoday's trials.224 
51 
Varmus and Satcher, supcorted by a broad array of AIDS 
researchers in developed2 and less developed226 countries, 
strongly defended the trials on the grounds that PCTs were 
scientifically necessary; an equivalency study between two 
interventions of unknown benefit would not make clear 
whether either intervention was more effective than no 
intervention. There were also confounding factors such as 
the relative toxicity of the interventions. Further, they 
argued that an ACTG 076 regimen group would be of little 
use since the regimen is unaffordable and unavailable in 
the host country. 
As Ronald Bayer suggests, this was not a clash over first 
principles, but a dispute over the application of agreed-upon 
principles in different social conditions.227 The established 
ethical principle is that human research subjects should not 
be denied the standard of care, but which standard-the 
prevalent standard achievable in the most advanced 
industrialized economy or the standard in the host country? 
In this context, policymakers had to make treatment 
decisions under conditions of poverty, scarcity, and urgent 
need. Everyone felt conflicted making these critical choices 
and would have liked to have had a uniform standard 
everywhere. The research subjects were informed, 
224 Varmus & Satcher, supra note 215, at 1004. 
225 Michael H. Merson, Letter to the Editor, 338 NEW ENG. J. MED. 836, 836 
(1998); Donald Francis, Letter to the Editor, 338 NEW ENG. J. MED. 837,837 (1998). 
226 Salim S. Abdool Karim, Placebo Controls in HN Perinatal Transmission 
Trials: A South African's Viewpoint, 88 AM. J. PuB. HEALTH 564, 564 (1998); Edward 
K. Mbidde, Letter to the Editor, 338 NEW ENG. J. MED. 837, 837 (1998). 
227 Bayer, supra note 213, at 567. 
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consented, and not exposed to risk; the study was designed 
to benefit host countries, which desired the research and 
ethically approved the protocol; and the results may vastly 
improve the lives of the world's poorest and most 
disadvantaged mothers and children. Given the social and 
economic context, it may have been unethical not to conduct 
the most rigorous and efficient international studies to 
prevent perinatal transmission in the least developed 
t · 228 co un nes. 
CONCLUSION 
Secretary General Kofi Annan [has] asked for seven 
billion dollars a year for a global fund to fight 
infectious diseases. I tell you, I've done a lot of work in 
this area. We can turn this epidemic around in three 
years. Brazil cut the death rate in half in three years 
with medicine and prevention. Uganda, with no 
medicine, cut the death rate in half in five years. We 
do not have to have 100 million AIDS cases in five 
years. We do not have to let countries be consumed by 
this. I promise you, fledgling democracies will be 
destroyed by this. They will not be able to sustain an 
AIDS caseload of 100 million. And we don't have to 
have it happen. We ought to fund this program. It's 
not very much money. 
William Jefferson Clinton, Former President of the 
United States (2001). 
The world is in the midst of one of the great pandemics in 
human history with untold suffering, illness, and death. 
The devastating social and economic effects are just as 
sobering as the health effects. One would expect the 
228 Catherine M. Wilfert et aI., Perinatal HN Intervention Research in Developing 
Countries Workshop Participants, Science, Ethics, and the Future of Research into 
Maternal Infant Transmission of HN·l, 353 LANCET 832,833 (1999). 
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international community to mobilize against a threat of this 
magnitude, but somehow there is complacency, even 
indifference, when there should be resolve and unity. As 
the toll of the pandemic rises, particularly in the poorest 
regions, there remains fierce debate about humanitarian 
assistance, property rights, and ethics. 
Given the level of need, there ought to be little 
disagreement that the more prosperous countries of North 
America and Europe should be devoting significant 
resources for education, prevention, and treatment in the 
poorer countries of Mrica and Southeast Asia. Yet, political 
leaders in developed countries have not viewed it in their 
self-interest to provide the kind of resources needed. Nor 
have many leaders in less developed countries given 
HIV/AIDS the kind of priority necessary to reduce the 
burden of disease. For complex and not well understood 
reasons, there has been an absence of political will to 
confront the HIV/AIDS pandemic. 
The private sector has also been unwilling to make the 
sacrifices necessary to make drugs and potential vaccines 
available in resource-poor markets. Transnational 
corporations, often supported by industrialized countries, 
have used international trade rules to safeguard their 
proprietary interests in AIDS medicines. This has resulted 
in higher prices and less access to these essential drugs in 
developing countries. Certainly, international public health 
agencies and some pharmaceutical companies have been 
working to reduce prices and increase access. Yet, most 
modern medications are still out-of-reach for the poor. 
There has even been sharp disagreement among ethicists. 
Some would require research subjects in the least developed 
countries to receive the standard of care available in the 
most developed countries. While this may provide benefits 
for persons directly participating in research trials, it may 
not be the best way to study the safety and efficacy of drug 
regimes that would be affordable in poor countries. This 
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disagreement has distracted attention from the vital issue 
of preventing perinatal transmission in less developed 
countries by ensuring that women and their infants have 
access to a range of care and services. 
The strategies needed to reduce significantly the burden 
of HIV/AIDS are well known and demonstrated to be 
effective. What is still needed are the economic resources 
and political will necessary to implement comprehensive 
programs for AIDS prevention and treatment in every 
region. 
